U.S. patent application number 12/029501 was filed with the patent office on 2008-06-19 for novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias.
This patent application is currently assigned to ASTRAZENECA AB. Invention is credited to Annika Bjore, Ulrik Gran, Gert Strandlund.
Application Number | 20080146812 12/029501 |
Document ID | / |
Family ID | 32710060 |
Filed Date | 2008-06-19 |
United States Patent
Application |
20080146812 |
Kind Code |
A1 |
Bjore; Annika ; et
al. |
June 19, 2008 |
Novel Oxabispidine Compounds And Their Use In The Treatment Of
Cardiac Arrhythmias
Abstract
There is provided compounds of formula I, wherein R.sup.1,
R.sup.2, R.sup.4, R.sup.41 to R.sup.46, A, B and G have meanings
given in the description, which are useful in the prophylaxis and
in the treatment of arrhythmias, in particular atrial and
ventricular arrhythmias. ##STR00001##
Inventors: |
Bjore; Annika; (Molndal,
SE) ; Gran; Ulrik; (Molndal, SE) ; Strandlund;
Gert; (Molndal, SE) |
Correspondence
Address: |
Pepper Hamilton LLP
400 Berwyn Park, 899 Cassatt Road
Berwyn
PA
19312-1183
US
|
Assignee: |
ASTRAZENECA AB
Sodertalje
SE
|
Family ID: |
32710060 |
Appl. No.: |
12/029501 |
Filed: |
February 12, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11570439 |
Dec 12, 2006 |
7354917 |
|
|
PCT/SE05/00890 |
Jun 13, 2005 |
|
|
|
12029501 |
|
|
|
|
Current U.S.
Class: |
546/282.7 ;
549/397 |
Current CPC
Class: |
A61P 9/00 20180101; C07D
498/08 20130101; A61P 9/06 20180101 |
Class at
Publication: |
546/282.7 ;
549/397 |
International
Class: |
C07D 405/02 20060101
C07D405/02; C07D 311/00 20060101 C07D311/00 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 15, 2004 |
SE |
0401540-0 |
Claims
1-38. (canceled)
39. A compound of formula I ##STR00021## wherein: G represents CH
or N; R.sup.41 to R.sup.46, independently, represent H or C.sub.1-3
alkyl; A represents C.sub.2-6 alkylene optionally interrupted by
--S(O).sub.2N(R.sup.18a)-- or --N(R)SO.sub.2-- and/or optionally
substituted by one or more substituents selected from --OH, halo,
and amino; R.sup.18a represents H or C.sub.1-6 alkyl; R.sup.2
represents --S(O).sub.2R.sup.3a, --C(O)OR.sup.3b, --C(O)R.sup.3c,
--C(O)N(R.sup.3d)(R.sup.3e) or --S(O).sub.2N(R.sup.3f)(R.sup.3g);
R.sup.3a to R.sup.3g, independently, represent C.sub.1-6 alkyl
(optionally substituted by one or more substituents selected from
halo, -E-aryl, -E-Het.sup.8, --C(O)R.sup.16a, --C(O)OR.sup.16b and
--C(O)N(R.sup.16c)R.sup.16d), aryl or Het.sup.9, or R.sup.3c and
R.sup.3d to R.sup.3g independently represent H; E represents, at
each occurrence when used herein, a direct bond or C.sub.1-4
alkylene; Het.sup.1 to Het.sup.11, independently, represent five-
to twelve-membered heterocyclic groups containing one or more
heteroatoms selected from oxygen nitrogen and/or sulfur, which
groups are optionally substituted by one or more substituents
selected from --OH, oxo, halo, cyano, nitro, C.sub.1-6 alkyl,
C.sub.1-6 alkoxy, aryl, aryloxy, --N(R.sup.17a)R.sup.17b,
--C(O)R.sup.17c, --C(O)OR.sup.17d, --C(O)N(R.sup.17e)R.sup.17f,
--N(R.sup.17g)C(O)R.sup.17h, --S(O)N(R.sup.17i)R.sup.17j and
--N(R.sup.17k)S(O).sub.2R.sup.17l; R.sup.16a to R.sup.16d,
independently, represent at each occurrence when used herein, H,
C.sub.1-6 alkyl (optionally substituted by one or more substituents
selected from halo, aryl and Het.sup.10) aryl Het.sup.11, or
R.sup.16c and R.sup.16d together represent C.sub.3-6 alkylene,
optionally interrupted by an O atom; R.sup.17a to R.sup.17l,
independently, represent C.sub.1-6 alkyl, aryl or R.sup.17a to
R.sup.17k independently represent H; B represents
-Z.sup.1-{[C(O)].sub.aC(H)(R.sup.19a)}.sub.b--,
-Z.sup.2-[C(O)].sub.cN(R.sup.19b)--, -Z.sup.2-S(O).sub.n--,
-Z.sup.2-N(R.sup.18c)S(O).sub.2--,
-Z.sup.2-S(O).sub.2N(R.sup.18d)-- or -Z.sup.2-O-- (in which six
groups Z.sup.1 or Z.sup.2 is attached to the nitrogen atom bearing
R.sup.2); a, b, and c, independently, represent 0 or 1; n
represents 0, 1 or 2; Z.sup.1 represents a direct bond or C.sub.1-4
alkylene, optionally interrupted by --N(R.sup.18e)S(O).sub.2-- or
--S(O).sub.2N(R.sup.18f)--; Z.sup.2 represents, at each occurrence
when used herein, C.sub.2-4 alkylene, optionally interrupted by
--N(R.sup.18g)S(O).sub.2-- or --S(O)N(R.sup.18h)--; R.sup.18c to
R.sup.18h, independently, represent H or C.sub.1-6 alkyl; R.sup.19a
represents H or, together with a single R.sup.4 substituent at a
position on the phenyl or pyridyl group that is ortho- to the
position at which the group B is attached, R.sup.19a represents
C.sub.2-4 alkylene optionally interrupted or terminated by O, S or
N(R.sup.20); R.sup.19b represents H, C.sub.1-6 alkyl or, together
with a single R.sup.4 substituent at a position on the phenyl or
pyridyl group that is ortho- to the position at which the group B
is attached, R.sup.19b represents C.sub.2-4 alkylene; R.sup.20
represents H or C.sub.1-6 alkyl R.sup.4 represents one or more
optional substituents selected from --OH, cyano, halo, nitro,
C.sub.1-6 alkyl (optionally terminated by --N(H)C(O)OR.sup.21a),
C.sub.1-6 alkoxy, --N(R.sup.22a)R.sup.22b, --C(O)R.sup.22c,
--C(O)OR.sup.22d, --C(O)N(R.sup.22e)R.sup.22f,
--N(R.sup.22g)C(O)R.sup.22h,
--N(R.sup.22i)C(O)N(R.sup.22j)R.sup.22k,
--N(R.sup.22m)S(O).sub.2R.sup.21b,
--S(O).sub.2N(R.sup.22n)R.sup.22o, --S(O).sub.2R.sup.21c,
--OS(O).sub.2R.sup.21d and aryl, and an R.sup.4 substituent in a
position on the phenyl or pyridyl group that is ortho- to the
position at which the group B is attached may (i) together with
R.sup.19a, represent C.sub.2-4 alkylene optionally interrupted or
terminated by O, S or N(R.sup.20), or (ii) together with R.sup.19b,
represent C.sub.2-4 alkylene; R.sup.20 represents H or C.sub.1-6
alkyl; R.sup.21a to R.sup.21d, independently represent C.sub.1-6
alkyl; R.sup.22a and R.sup.22b, independently represent H,
C.sub.1-6 alkyl or together represent C.sub.3-6 alkylene, resulting
in a four- to seven-membered nitrogen-containing ring; and
R.sup.22c to R.sup.22o, independently represent H or C.sub.1-6
alkyl; R.sup.1 represents C.sub.1-12 alkyl (which alkyl group is
optionally substituted by one or more groups selected from halo,
cyano, nitro, aryl Het.sup.1, --C(O)R.sup.5a, --OR.sup.5b,
--N(R.sup.6)R.sup.5c, --C(O)XR.sup.7, --C(O)N(R.sup.8a)R.sup.5d,
--OC(O)N(R.sup.8b)R.sup.5e, --S(O).sub.2R.sup.9a,
--S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d); X is O or S; R.sup.5a to
R.sup.5e, independently, represent at each occurrence when used
herein, H, C.sub.1-6 alkyl (which latter group is optionally
substituted by one or more substituents selected from --OH, halo,
cyano, nitro, aryl, aryloxy, Het.sup.2,
--S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d), aryl or Het.sup.3, or R.sup.5d or
R.sup.5e, together with, respectively R.sup.8a or R.sup.8b, may
represent C.sub.3-6 alkylene (which alkylene group is optionally
interrupted by an O atom and/or is optionally substituted by one or
more C.sub.1-3 alkyl groups); R.sup.6 represents H, C.sub.1-6 alkyl
(optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro, aryl, --S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d), aryl, --C(O)R.sup.10a,
--C(O)OR.sup.10b, --C(O)N(R.sup.10c)R.sup.10d or
--S(O).sub.2R.sup.10e; R.sup.10a to R.sup.10e, independently,
represent C.sub.1-6 alkyl (optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro and aryl), aryl
or R.sup.10a, R.sup.10c or R.sup.10d represents H; R.sup.7
represents, at each occurrence when used herein, C.sub.1-12 alkyl
(optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro, aryl, C.sub.1-6 alkoxy Het.sup.4,
--S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d); R.sup.8a and R.sup.8b
independently represent H, C.sub.1-12 alkyl, C.sub.1-6 alkoxy
(which latter two groups are optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro, C.sub.1-4
alkyl, C.sub.1-4 alkoxy, --S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d), -D-aryl, -D-aryloxy,
-D-Het.sup.5, -D-N(H)C(O)R.sup.11a, -D-S(O).sub.2R.sup.12a,
-D-C(O)R.sup.11b, -D-C(O)OR.sup.12b, -D-C(O)N(R.sup.11c)R.sup.11d,
or R.sup.8a or R.sup.8b, together with, respectively, R.sup.5d or
R.sup.5e, may represent C.sub.3-6 alkylene (which alkylene group is
optionally interrupted by an O atom and/or is optionally
substituted by one or more C.sub.1-3 alkyl groups); R.sup.9a
represents at each occurrence when used herein, C.sub.1-6 alkyl
(optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro, aryl, --S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d) or aryl; R.sup.9b represents at
each occurrence when used herein H or C.sub.1-6 alkyl; R.sup.9c and
R.sup.9d, independently, represent at each occurrence when used
herein C.sub.1-6 alkyl (optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro, aryl and
Het.sup.6), aryl or Het.sup.7, or R.sup.9c represents H; R.sup.11a
to R.sup.11d, independently, represent H, C.sub.1-6 alkyl
(optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro and aryl), aryl, or R.sup.11c and
R.sup.11d together represent C.sub.1-6 alkylene; R.sup.12a and
R.sup.12b, independently, represent C.sub.1-6 alkyl (optionally
substituted by one or more substituents selected from --OH, halo,
cyano, nitro and aryl) or aryl; and D represents at each occurrence
when used herein a direct bond or C.sub.1-6 alkylene; wherein each
aryl and aryloxy group unless otherwise specified, is optionally
substituted; in combination with another drug for use as a
medicament for the treatment of arrhythmia or a cardiovascular
disorder.
40-45. (canceled)
46. A compound of claim 39 in combination with an
anticoagulant.
47. A compound of claim 46 wherein the anticoagulant is a substance
selected from aspirin, warfarin, enoxaparin, heparin, low molecular
weight heparin, cilostazol, clopidogrel, ticlopidine, tirofiban,
abciximab, dipyridamole, plasma protein fraction, human albumin,
low molecular weight dextran, hetastarch, reteplase, alteplase,
streptokinase, urokinase, dalteparin, filgrastin, immunoglogulin,
ginkolide B, hirudins, foropafant, rocepafant, bivalirudin,
dermatan sulfate mediolanum, eptilibatide, tirofiban,
thrombomodulin, abcxmab, low molecular weight dermatan
sulfate-opocrin, eptacog alfa, argatroban, fondaparinux sodium,
tifacogin, lepirudin, desirudin, OP2000, roxifiban, parnaparin
sodium, human hemoglobin, bovine hemoglobin, human hemoglobin,
antithrombin III, RSR 13, heparin-oral transgenic antithrombin III,
H37695, enoxaparin sodium, mesoglycan, CTC 111, bivalirudin, or any
combination thereof.
48. A compound of claim 47 wherein the anticoagulant is aspirin or
warfarin.
49. A compound of claim 46 wherein the anticoagulant is a thrombin
inhibitor.
50. A compound of claim 49 wherein the thrombin inhibitor is a low
molecular weight thrombin inhibitor.
51. A compound of claim 50 wherein the low molecular weight
thrombin inhibitor is a low molecular weight peptide-based, amino
acid-based, and/or peptide analogue-based, thrombin inhibitor.
52. A compound of claim 51 wherein the low molecular weight
peptide-based thrombin inhibitor is a gatran.
53. A compound of claim 52 wherein the gatran is inogatran or
melagatran.
Description
FIELD OF THE INVENTION
[0001] This invention relates to novel pharmaceutically useful
compounds, in particular compounds which are useful in the
treatment of cardiac arrhythmias.
BACKGROUND AND PRIOR ART
[0002] Cardiac arrhythmias may be defined as abnormalities in the
rate, regularity, or site of origin of the cardiac impulse or as
disturbances in conduction which causes an abnormal sequence of
activation. Arrhythmias may be classified clinically by means of
the presumed site of origin (i.e. as supraventricular, including
atrial and atrioventricular, arrhythmias and ventricular
arrhythmias) and/or by means of rate (i.e. bradyarrhythmias (slow)
and tachyarrhythmias (fast)).
[0003] In the treatment of cardiac arrhythmias, the negative
outcome in clinical trials (see, for example, the outcome of the
Cardiac Arrhythmia Suppression Trial (CAST) reported in New England
Journal of Medicine, 321, 406 (1989)) with "traditional"
antiarrhythmic drugs, which act primarily by slowing the conduction
velocity (class I antiarrhythmic drugs), has prompted drug
development towards compounds which selectively delay cardiac
repolarization, thus prolonging the QT interval. Class III
antiarrhythmic drugs may be defined as drugs which prolong the
trans-membrane action potential duration (which can be caused by a
block of outward K.sup.+ currents or from an increase of inward ion
currents) and refractoriness, without affecting cardiac
conduction.
[0004] One of the key disadvantages of hitherto known drugs which
act by delaying repolarization (class III or otherwise) is that
they all are known to exhibit a unique form of proarrhythmia known
as torsades de pointes (turning of points), which may, on occasion
be fatal. From the point of view of safety, the minimisation of
this phenomenon (which has also been shown to be exhibited as a
result of administration of non-cardiac drugs such as
phenothiazines, tricyclic antidepressants, antihistamines and
antibiotics) is a key problem to be solved in the provision of
effective antiarrhythmic drugs.
[0005] Antiarrhythmic drugs based on bispidines
(3,7-diazabicyclo[3.3.1]nonanes), are known from inter alia
international patent applications WO 91/07405 and WO 99/31100,
European patent applications 306 871, 308 843 and 655 228 and U.S.
Pat. Nos. 3,962,449, 4,556,662, 4,550,112, 4,459,301 and 5,468,858,
as well as journal articles including, inter alia, J. Med. Chem.
39, 2559, (1996), Pharmacol. Res., 24, 149 (1991), Circulation, 90,
2032 (1994) and Anal. Sci. 9, 429, (1993).
[0006] Certain oxabispidine compounds are disclosed as chemical
curiosities in Chem. Ber., 96, 2872 (1963). The use of certain
other oxabispidine compounds in the treatment of cardiac
arrhythmias is disclosed in WO 01/28992. Methods for the
preparation of such oxabispidine compounds are disclosed in WO
02/28863, WO 02/28864, WO 02/83690 and WO 02/83691. Oxabispidine
compounds of formula I, as defined below, are neither disclosed nor
suggested by any of these documents.
[0007] We have surprisingly found that a novel group of
oxabispidine-based compounds exhibit electrophysiological activity,
and are therefore expected to be useful in the treatment of cardiac
arrhythmias. The novel group of oxabispidine-based compounds has
advantageous properties compared to compounds of the prior art,
such as enhanced potency, enhanced selectivity, and/or reduction of
total clearance. These advantageous properties can distinguish the
use of such compounds as pharmaceutical agents by lowering the
daily clinical dose, lengthening the duration of action, and/or
improving the side effect profile.
DISCLOSURE OF THE INVENTION
[0008] According to the invention there is provided compounds of
formula I,
##STR00002##
wherein R.sup.1 represents C.sub.1-12 alkyl (which alkyl group is
optionally substituted by one or more groups selected from halo,
cyano, nitro, aryl, Het.sup.1, --C(O)R.sup.5a, --OR.sup.5b,
--N(R.sup.6)R.sup.5c, C(O)XR.sup.7, --C(O)N(R.sup.8a)R.sup.5d,
--OC(O)N(R.sup.8b)R.sup.5e, --S(O).sub.2R.sup.9a,
--S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d) or R.sup.1 represents
--C(O)XR.sup.7, C(O)N(R.sup.8a)R.sup.5d or --S(O).sub.2R.sup.9a;
R.sup.5a to R.sup.5e independently represent, at each occurrence
when used herein, H, C.sub.1-6 alkyl (which latter group is
optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro, aryl, aryloxy, Het.sup.2,
--S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d), aryl or Het.sup.3, or R.sup.5d or
R.sup.5e, together with, respectively, R.sup.8a or R.sup.8b, may
represent C.sub.3-6 alkylene (which alkylene group is optionally
interrupted by an O atom and/or is optionally substituted by one or
more C.sub.1-3 alkyl groups); R.sup.6 represents H, C.sub.1-6 alkyl
(optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro, aryl, --S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d), aryl, --C(O)R.sup.10a,
--C(O)OR.sup.10b, C(O)N(R.sup.10c)R.sup.10d or
--S(O).sub.2R.sup.10e; R.sup.10a to R.sup.10e independently
represent C.sub.1-6 alkyl (optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro and aryl),
aryl, or R.sup.10a, R.sup.10c or R.sup.10d represents H; R.sup.7
represents, at each occurrence when used herein, C.sub.1-12 alkyl
(optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro, aryl, C.sub.1-6 alkoxy, Het.sup.4,
--S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d); R.sup.8a and R.sup.8b
independently represent H, C.sub.1-12 alkyl, C.sub.1-6 alkoxy
(which latter two groups are optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro, C.sub.1-4
alkyl, C.sub.1-4 alkoxy, --S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d), -D-aryl, -D-aryloxy,
-D-Het.sup.5, -D-N(H)C(O)R.sup.11a, -D-S(O).sub.2R.sup.12a,
D-C(O)R.sup.11b, -D-C(O)OR.sup.12b, -D-C(O)N(R.sup.11c)R.sup.11d,
or R.sup.8a or R.sup.8b, together with, respectively, R.sup.5d or
R.sup.5e, may represent C.sub.3-6 alkylene (which alkylene group is
optionally interrupted by an O atom and/or is optionally
substituted by one or more C.sub.1-3 alkyl groups); R.sup.11a to
R.sup.11d independently represent H, C.sub.1-6 alkyl (optionally
substituted by one or more substituents selected from --OH, halo,
cyano, nitro and aryl), aryl, or R.sup.11c and R.sup.11d together
represent C.sub.3-6 alkylene; R.sup.12a and R.sup.12b independently
represent C.sub.1-6 alkyl (optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro and aryl) or
aryl; D represents, at each occurrence when used herein, a direct
bond or C.sub.1-6 alkylene; X represents O or S; R.sup.9a
represents, at each occurrence when used herein, C.sub.1-6 alkyl
(optionally substituted by one or more substituents selected from
--OH, halo, cyano, nitro, aryl, --S(O).sub.2N(R.sup.9b)R.sup.9c and
--N(R.sup.9b)S(O).sub.2R.sup.9d) or aryl; R.sup.9b represents, at
each occurrence when used herein, H or C.sub.1-6 alkyl; R.sup.9c
and R.sup.9d independently represent, at each occurrence when used
herein, C.sub.1-6 alkyl (optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro, aryl and
Het.sup.6), aryl or Het.sup.7, or R.sup.9c represents H; R.sup.2
represents --S(O).sub.2R.sup.3a, C(O)OR.sup.3b, --C(O)R.sup.3c,
C(O)N(R.sup.3d)(R.sup.3e) or --S(O).sub.2N(R.sup.3f)(R.sup.3g);
R.sup.3a to R.sup.3g independently represent C.sub.1-6 alkyl
(optionally substituted by one or more substituents selected from
halo, -E-aryl, -E-Het.sup.8, --C(O)R.sup.16a, --C(O)OR.sup.16b and
--C(O)N(R.sup.16c)R.sup.16d), aryl or Het.sup.9, or R.sup.3c and
R.sup.3d to R.sup.3g independently represent H; R.sup.16a to
R.sup.16d independently represent, at each occurrence when used
herein, H, C.sub.1-6 alkyl (optionally substituted by one or more
substituents selected from halo, aryl and Het.sup.10), aryl,
Het.sup.11, or R.sup.16c and R.sup.16d together represent C.sub.3-6
alkylene, optionally interrupted by an O atom; E represents, at
each occurrence when used herein, a direct bond or C.sub.1-4
alkylene;
[0009] Het.sup.1 to Het.sup.11 independently represent five- to
twelve-membered heterocyclic groups containing one or more
heteroatoms selected from oxygen, nitrogen and/or sulfur, which
groups are optionally substituted by one or more substituents
selected from --OH, oxo, halo, cyano, nitro, C.sub.1-6 alkyl,
C.sub.1-6 alkoxy, aryl, aryloxy, N(R.sup.17a)R.sup.17b,
C(O)R.sup.17c, C(O)OR.sup.17d, --C(O)N(R.sup.17e)R.sup.17f,
--N(R.sup.17g)C(O)R.sup.17h, --S(O).sub.2N(R.sup.17i)R.sup.17j and
--N(R.sup.17k)S(O).sub.2R.sup.17l;
R.sup.17a to R.sup.17l independently represent C.sub.1-6 alkyl,
aryl or R.sup.17a to R.sup.17k independently represent H; A
represents C.sub.2-6 alkylene optionally interrupted by
--S(O).sub.2N(R.sup.18a)-- or --N(R.sup.18b)S(O).sub.2-- and/or
optionally substituted by one or more substituents selected from
--OH, halo and amino; B represents
-Z.sup.1-{[C(O)].sub.aC(H)(R.sup.19a)}.sub.b--,
-Z.sup.2-[C(O)].sub.cN(R.sup.19b)--, -Z.sup.2-S(O).sub.n--,
-Z.sup.2-N(R.sup.18c)S(O).sub.2--,
-Z.sup.2-S(O).sub.2N(R.sup.18d)-- or -Z.sup.2-O-- (in which six
groups Z.sup.1 or Z.sup.2 is attached to the nitrogen atom bearing
R.sup.2); Z.sup.1 represents a direct bond or C.sub.1-4 alkylene,
optionally interrupted by --N(R.sup.18e)S(O).sub.2-- or
--S(O).sub.2N(R.sup.18f)--; Z.sup.2 represents, at each occurrence
when used herein, C.sub.2-4 alkylene, optionally interrupted by
--N(R.sup.18g)S(O).sub.2-- or --S(O).sub.2N(R.sup.18h)--; a, b and
c independently represent 0 or 1; n represents 0, 1 or 2; R.sup.18a
to R.sup.18h independently represent H or C.sub.1-6 alkyl;
R.sup.19a represents H or, together with a single R.sup.4
substituent at a position on the phenyl or pyridyl group that is
ortho- to the position at which the group B is attached, R.sup.19a
represents C.sub.2-4 alkylene optionally interrupted or terminated
by O, S or N(R.sup.20); R.sup.19b represents H, C.sub.1-6 alkyl or,
together with a single R.sup.4 substituent at a position on the
phenyl or pyridyl group that is ortho- to the position at which the
group B is attached, R.sup.19b represents C.sub.2-4 alkylene;
R.sup.20 represents H or C.sub.1-6 alkyl; G represents CH or N;
R.sup.4 represents one or more optional substituents selected from
--OH, cyano, halo, nitro, C.sub.1-6 alkyl (optionally terminated by
--N(H)C(O)OR.sup.21a), C.sub.1-6 alkoxy, --N(R.sup.22a)R.sup.22b,
--C(O)R.sup.22c, C(O)OR.sup.22d, C(O)N(R.sup.22e)R.sup.22f,
--N(R.sup.22g)C(O)R.sup.22h,
--N(R.sup.22i)C(O)N(R.sup.22j)R.sup.22k,
--N(R.sup.22m)S(O).sub.2R.sup.21b,
--S(O).sub.2N(R.sup.22a)R.sup.22o, --S(O).sub.2R.sup.21c,
--OS(O).sub.2R.sup.21d and aryl, and an R.sup.4 substituent in a
position on the phenyl or pyridyl group that is ortho- to the
position at which the group B is attached may [0010] (i) together
with R.sup.19a, represent C.sub.2-4 alkylene optionally interrupted
or terminated by O, S or N(R.sup.20c), or [0011] (ii) together with
R.sup.19b, represent C.sub.2-4 alkylene; R.sup.21a to R.sup.21d
independently represent C.sub.1-6 alkyl; R.sup.22a and R.sup.22b
independently represent H, C.sub.1-6 alkyl or together represent
C.sub.3-6 alkylene, resulting in a four- to seven-membered
nitrogen-containing ring; R.sup.22c to R.sup.22o independently
represent H or C.sub.1-6 alkyl; and R.sup.41 to R.sup.46
independently represent H or C.sub.1-3 alkyl; wherein each aryl and
aryloxy group, unless otherwise specified, is optionally
substituted; or a pharmaceutically acceptable derivative thereof;
which compounds are referred to hereinafter as "the compounds of
the invention".
[0012] For the avoidance of doubt it is to be understood that where
in this specification a group is qualified by `hereinbefore
defined`, `defined hereinbefore` or `defined above` the said group
encompasses the first occurring and broadest definition as well as
each and all of the other definitions for that group.
[0013] Unless otherwise specified, alkyl groups and alkoxy groups
as defined herein may be straight-chain or, when there is a
sufficient number (i.e. a minimum of three) of carbon atoms be
branched-chain, and/or cyclic. Further, when there is a sufficient
number (i.e. a minimum of four) of carbon atoms, such alkyl and
alkoxy groups may also be part cyclic/acyclic. Such alkyl and
alkoxy groups may also be saturated or, when there is a sufficient
number (i.e. a minimum of two) of carbon atoms, be unsaturated
and/or interrupted by one or more oxygen and/or sulfur atoms.
Unless otherwise specified, alkyl and alkoxy groups may also be
substituted by one or more halo, and especially fluoro, atoms.
[0014] Unless otherwise specified, alkylene groups as defined
herein may be straight-chain or, when there is a sufficient number
(i.e. a minimum of two) of carbon atoms, be branched-chain. Such
alkylene chains may also be saturated or, when there is a
sufficient number (i.e. a minimum of two) of carbon atoms, be
unsaturated and/or interrupted by one or more oxygen and/or sulfur
atoms. Unless otherwise specified, alkylene groups may also be
substituted by one or more halo atoms.
[0015] The term "aryl", when used herein, includes C.sub.6-10 aryl
groups such as phenyl, naphthyl and the like. The term "aryloxy",
when used herein includes C.sub.6-10 aryloxy groups such as
phenoxy, naphthoxy and the like. For the avoidance of doubt,
aryloxy groups referred to herein are attached to the rest of the
molecule via the O-atom of the oxy-group. Unless otherwise
specified, aryl and aryloxy groups may be substituted by one or
more substituents including --OH, halo, cyano, nitro, C.sub.1-6
alkyl, C.sub.1-6 alkoxy, N(R.sup.22a)R.sup.22b, --C(O)R.sup.22c,
--C(O)OR.sup.22d, C(O)N(R.sup.22e)R.sup.22f,
--N(R.sup.22g)C(O)R.sup.22h, --N(R.sup.22m)S(O).sub.2R.sup.21b,
--S(O).sub.2N(R.sup.22n)R.sup.22o, --S(O).sub.2R.sup.21c, and/or
--OS(O).sub.2R.sup.21d (wherein R.sup.21b to R.sup.21d and
R.sup.22a to R.sup.22o are as hereinbefore defined). When
substituted, aryl and aryloxy groups are preferably substituted by
between one and three substituents.
[0016] The term "halo", when used herein, includes fluoro, chloro,
bromo and iodo.
[0017] Het (Het.sup.1, Het.sup.2, Het.sup.3, Het.sup.4, Het.sup.5,
Het.sup.6, Het.sup.7, Het.sup.8, Het.sup.9, Het.sup.10 and
Het.sup.11) groups that may be mentioned include those containing 1
to 4 heteroatoms (selected from the group oxygen, nitrogen and/or
sulfur) and in which the total number of atoms in the ring system
are between five and twelve. Het (Het.sup.1, Het.sup.2, Het.sup.3,
Het.sup.4, Het.sup.5, Het.sup.6, Het.sup.7, Het.sup.8, Het.sup.9,
Het.sup.10 and Het.sup.11) groups may be fully saturated, wholly
aromatic, partly aromatic and/or bicyclic in character.
Heterocyclic groups that may be mentioned include
1-azabicyclo[2.2.2]octanyl, benzimidazolyl, benzisoxazolyl,
benzodioxanyl, benzodioxepanyl, benzodioxolyl, benzofuranyl,
benzofurazanyl, benzomorpholinyl, 2,1,3-benzoxadiazolyl,
benzoxazinonyl, benzoxazolidinyl, benzoxazolyl, benzopyrazolyl,
benzo[e]pyrimidine, 2,1,3-benzothiadiazolyl, benzothiazolyl,
benzothienyl, benzotriazolyl, chromanyl, chromenyl, cinnolinyl,
2,3-dihydrobenzimidazolyl, 2,3-dihydrobenzo[b]furanyl,
1,3-dihydrobenzo[c]furanyl, 2,3-dihydropyrrolo[2,3-b]pyridinyl,
dioxanyl, furanyl, hexahydropyrimidinyl, hydantoinyl, imidazolyl,
imidazo[1,2-a]pyridinyl, imidazo[2,3-b]thiazolyl, indolyl,
isoquinolinyl, isoxazolyl, maleimido, morpholinyl, oxadiazolyl,
1,3-oxazinanyl, oxazolyl, phthalazinyl, piperazinyl, piperidinyl,
purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl,
pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, pyrrolo[2,3-b]pyridinyl,
pyrrolo[5,1-b]pyridinyl, pyrrolo[2,3-c]pyridinyl, pyrrolyl,
quinazolinyl, quinolinyl, sulfolanyl, 3-sulfolenyl,
4,5,6,7-tetrahydrobenzimidazolyl, 4,5,6,7-tetrahydrobenzopyrazolyl,
5,6,7,8-tetrahydrobenzo[e]-pyrimidine, tetrahydrofuranyl,
tetrahydropyranyl, 3,4,5,6-tetrahydropyridinyl,
1,2,3,4-tetrahydropyrimidinyl, 3,4,5,6-tetrahydropyrimidinyl,
thiadiazolyl, thiazolidinyl, thiazolyl, thienyl,
thieno[5,1-c]pyridinyl, thiochromanyl, triazolyl,
1,3,4-triazolo[2,3-b]pyrimidinyl and the like.
[0018] Values of Het.sup.1 that may be mentioned include
2,3-dihydrobenzo[b]furanyl, furanyl, imidazolyl, isoxazolyl,
pyridinyl and thiazolyl.
[0019] Substituents on Het (Het.sup.1, Het.sup.2, Het.sup.3,
Het.sup.4, Het.sup.5, Het.sup.6, Het.sup.7, Het.sup.8, Het.sup.9,
Het.sup.10 and Het.sup.11) groups may, where appropriate, be
located on any atom in the ring system including a heteroatom. The
point of attachment of Het (Het.sup.1, Het.sup.2, Het.sup.3,
Het.sup.4, Het.sup.5, Het.sup.6, Het.sup.7, Het.sup.8, Het.sup.9,
Het.sup.10 and Het.sup.11) groups may be via any atom in the ring
system including (where appropriate) a heteroatom, or an atom on
any fused carbocyclic ring that may be present as part of the ring
system. Het (Het.sup.1, Het.sup.2, Het.sup.3, Het.sup.4, Het.sup.5,
Het.sup.6, Het.sup.7, Het.sup.8, Het.sup.9, Het.sup.10 and
Het.sup.11) groups may also be in the N- or S-oxidised form.
[0020] Pharmaceutically acceptable derivatives include salts and
solvates. Salts which may be mentioned include acid addition salts.
Pharmaceutically acceptable derivatives also include, at the
oxabispidine or (when G represents N) pyridyl nitrogens, C.sub.1-4
alkyl quaternary ammonium salts and N-oxides, provided that when a
N-oxide is present: [0021] (a) no Het (Het.sup.1, Het.sup.2,
Het.sup.3, Het.sup.4, Het.sup.5, Het.sup.6, Het.sup.7, Het.sup.8,
Het.sup.9, Het.sup.10 and Het.sup.11) group contains an unoxidised
S-atom; and/or [0022] (b) n does not represent 0 when B represents
-Z.sup.2-S(O).sub.n--.
[0023] The compounds of the invention may exhibit tautomerism. All
tautomeric forms and mixtures thereof are included within the scope
of the invention.
[0024] The compounds of the invention may also contain one or more
asymmetric carbon atoms and may therefore exhibit optical and/or
diastereoisomerism.
[0025] Diastereoisomers may be separated using conventional
techniques, e.g. chromatography or fractional crystallisation. The
various stereoisomers may be isolated by separation of a racemic or
other mixture of the compounds using conventional, e.g. fractional
crystallisation or HPLC, techniques. Alternatively the desired
optical isomers may be made by reaction of the appropriate
optically active starting materials under conditions which will not
cause racemisation or epimerisation, or by derivatisation, for
example with a homochiral acid followed by separation of the
diastereomeric esters by conventional means (e.g. HPLC,
chromatography over silica). All stereoisomers are included within
the scope of the invention.
[0026] Abbreviations are listed at the end of this
specification.
[0027] Preferred values of each variable group are as follows. Such
values may be used where appropriate with any of the values,
definitions, claims, aspects or embodiments defined hereinbefore or
hereinafter. In particular, each may be used as an individual
limitation on the broadest definition of formula (I).
[0028] Particular values of each variable group are as follows.
Such values may be used where appropriate with any of the values,
definitions, claims, aspects or embodiments defined hereinbefore or
hereinafter. In particular, each may be used as an individual
limitation on the broadest definition of formula (I). R.sup.1
represents C.sub.1-4 alkyl, which alkyl group is substituted by at
least one-phenyl or phenoxy group (both optionally substituted by
one or more halo, cyano, methyl, methoxy, fluoromethoxy,
difluoromethoxy or trifluoromethoxy groups);
A represents a direct bond or C.sub.1-3 alkylene (such as a C.sub.2
alkylene); B represents a direct bond, C.sub.1-3 alkylene (such as
a C.sub.2 alkylene), or C.sub.1-3 alkoxy (such as a C.sub.2 alkoxy,
in which the oxygen is attached to the phenyl group that is
optionally substituted with R.sup.4); R.sup.2 represents
--S(O).sub.2R.sup.3a, --C(O)OR.sup.3b, --C(O)R.sup.3c or
C(O)N(R.sup.3d)R.sup.3e; R.sup.3a to R.sup.3b each independently
represent hydrogen or C.sub.1-3 alkyl (such as methyl, ethyl,
isopropyl or propyl); G represents carbon; R.sup.41 to R.sup.46
represents hydrogen; and R.sup.4 represents one or more optional
substituents selected from cyano and/or halo (such as fluoro) and
an R.sup.4 substituent is in a position on the phenyl group that is
ortho- and/or para- to the position at which the group B is
attached.
[0029] Preferred compounds of the invention include those in
which:
R.sup.1 represents C.sub.1-8 alkyl (which alkyl group is optionally
substituted by one or more groups selected from halo, aryl (which
latter group is optionally substituted by one or more substituents
selected from --OH, halo, cyano, nitro, C.sub.1-5 alkyl, C.sub.1-4
alkoxy (which latter two groups are optionally substituted by one
or more halo atoms), --C(O)R.sup.22c and --S(O).sub.2R.sup.21c),
Het.sup.1, --C(O)R.sup.5a, --OR.sup.5b, --N(R.sup.6)R.sup.5c,
C(O)N(R.sup.8a)R.sup.5d, --OC(O)N(R.sup.8b)R.sup.5e,
--S(O).sub.2R.sup.9a, --S(O).sub.2N(H)R.sup.9c and
--N(H)S(O).sub.2R.sup.9d) or R.sup.1 represents --C(O)OR.sup.7,
--C(O)N(R.sup.8a)R.sup.5d or --S(O).sub.2R.sup.9a; R.sup.5a to
R.sup.5e independently represent, at each occurrence when used
herein, H, C.sub.1-6 alkyl (which latter group is optionally
substituted by one or more substituents selected from cyano, nitro,
optionally substituted aryl and optionally substituted aryloxy),
aryl (which latter group is optionally substituted by one or more
substituents selected from --OH, halo, cyano, nitro,
N(R.sup.22a)R.sup.22b (in which latter group R.sup.22a and
R.sup.22b together represent C.sub.3-6 alkylene), C.sub.1-5 alkyl
and C.sub.1-5 alkoxy (which latter two groups are optionally
substituted by one or more halo atoms)), Het.sup.3, or R.sup.5d,
together with R.sup.8a, represents C.sub.4-5 alkylene (which
alkylene group is optionally interrupted by an O atom); R.sup.6
represents H, C.sub.1-6 alkyl, optionally substituted aryl
--C(O)R.sup.10a, --C(O)OR.sup.10b, --C(O)N(R.sup.10c)R.sup.10d or
--S(O).sub.2R.sup.10e; R.sup.10a, R.sup.10b and R.sup.10e
independently represent C.sub.1-5 alkyl (optionally substituted by
one or more substituents selected from halo and optionally
substituted aryl) or optionally substituted aryl; R.sup.10c and
R.sup.10d independently represent H or C.sub.1-4 alkyl; R.sup.7
represents C.sub.1-6 alkyl (optionally substituted by one or more
substituents selected from halo, optionally substituted aryl,
C.sub.1-4 alkoxy and Het.sup.4); R.sup.8a and R.sup.8b
independently represent H, C.sub.1-6 alkyl (which latter group is
optionally substituted by one or more substituents selected from
halo, cyano and nitro), -D-(optionally substituted aryl),
-D-(optionally substituted aryloxy), -D-Het.sup.5,
-D-N(H)C(O)R.sup.11a, -D-C(O)R.sup.11b, or R.sup.8a, together with
R.sup.5d represents C.sub.4-5 alkylene (which alkylene group is
optionally interrupted by an O atom); R.sup.11a and R.sup.11d
independently represent C.sub.1-4 alkyl (optionally substituted by
one or more substituents selected from halo, cyano, nitro and
optionally substituted aryl) or optionally substituted aryl; D
represents, at each occurrence when used herein, a direct bond or
C.sub.1-4 alkylene; R.sup.9a represents, C.sub.1-6 alkyl
(optionally substituted by one or more halo groups) or optionally
substituted aryl; R.sup.9c and R.sup.9d independently represent, at
each occurrence when used herein, C.sub.1-5 alkyl (optionally
substituted by one or more substituents selected from halo,
optionally substituted aryl and Het.sup.6), optionally substituted
aryl or Het.sup.7, or R.sup.9c represents H; R.sup.2 represents
--S(O).sub.2R.sup.3a, --C(O)OR.sup.3b, --C(O)R.sup.3c or
--C(O)N(R.sup.3d)R.sup.3e; R.sup.3a to R.sup.3e independently
represent C.sub.1-5 alkyl (optionally substituted by one or more
substituents selected from halo, optionally substituted aryl and
Het.sup.8), optionally substituted aryl or Het.sup.9, or R.sup.3d
represents H; Het.sup.1 and Het.sup.3 to Het.sup.9 independently
represent four- to ten-membered heterocyclic groups containing one
to four heteroatoms selected from oxygen, nitrogen and/or sulfur,
which groups are optionally substituted by one or more substituents
selected from --OH, oxo, halo, cyano, C.sub.1-4 alkyl, C.sub.1-4
alkoxy, phenyl, --N(H)R.sup.17a, --C(O)R.sup.17c,
--N(H)C(O)R.sup.17h and --N(H)S(O).sub.2R.sup.17j; R.sup.17a,
R.sup.17c, R.sup.17h and R.sup.17j independently represent
C.sub.1-4 alkyl or optionally substituted aryl or R.sup.17a,
R.sup.17c and R.sup.17h independently represent H; A represents
C.sub.2-4 alkylene optionally substituted by one or more
substituents selected from --OH and amino; B represents -Z.sup.1-,
-Z.sup.2-N(H)--, -Z.sup.2-C(O)N(R.sup.19b)--,
-Z.sup.2-S(O).sub.2--, -Z.sup.2-N(H)S(O).sub.2--,
-Z.sup.2-S(O).sub.2N(H)-- or -Z.sup.2-O-- (in which latter six
groups, Z.sup.2 is attached to the nitrogen atom bearing R.sup.2);
Z.sup.1 represents a direct bond or C.sub.1-4 alkylene; Z.sup.2
represents C.sub.2-4 alkylene; R.sup.19b represents H, C.sub.1-4
alkyl, or, together with a single R.sup.4 substituent at a position
on the phenyl or pyridyl group that is ortho- to the position at
which the group B is attached, R.sup.19b represents C.sub.2-4
alkylene; when G represents N, G is in the ortho- or, in
particular, the para-position relative to the point of attachment
of B; when G represents N, R.sup.4 is absent or represents a single
cyano group; R.sup.4 is absent (i.e. represents H) or represents
one or more substituents selected from --OH, cyano, halo, nitro,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, --C(O)N(R.sup.22e)R.sup.22f, and
--N(R.sup.22m)S(O).sub.2--C.sub.1-4 alkyl, or an R.sup.4
substituent in a position on the phenyl or pyridyl group that is
ortho- to the position at which the group B is attached may,
together with R.sup.19b, represent C.sub.2-4 alkylene; R.sup.21c
represents C.sub.1-4 alkyl; R.sup.22c, R.sup.22e, R.sup.22f and
R.sup.22m independently represent H or C.sub.1-4 alkyl; R.sup.41 to
R.sup.46 independently represent H; optional substituents on aryl
and aryloxy groups are, unless otherwise stated, one or more
substituents selected from halo, cyano, nitro, C.sub.1-4 alkyl,
C.sub.1-4 alkoxy (which latter two groups are optionally
substituted by one or more halo atoms), --N(H)S(O).sub.2R.sup.21b
and --S(O).sub.2N(H)R.sup.22o.
[0030] More preferred compounds of the invention include those in
which:
R.sup.1 represents straight- or branched-chain or part
cyclic/acyclic C.sub.1-6 alkyl, which alkyl group is optionally
interrupted by oxygen and/or substituted by: (i) one or more halo
or OR.sup.5b groups; and/or (ii) one group selected from phenyl
(which latter group is optionally substituted by one or more (e.g.
one to three) substituents selected from halo, cyano, C.sub.1-4
alkyl, C.sub.1-3 alkoxy (which latter two groups are optionally
substituted by one or more halo (e.g. fluoro) atoms),
--C(O)--C.sub.1-3 alkyl and --S(O).sub.2--C.sub.1-4 alkyl),
Het.sup.1, --C(O)R.sup.5a, --N(R.sup.6)R.sup.5c,
--C(O)N(R.sup.8a)R.sup.5d, --OC(O)N(H)R.sup.8b and
--S(O).sub.2--C.sub.1-4 alkyl, or R.sup.1 represents
--C(O)OR.sup.7, --C(O)N(R.sup.8a)R.sup.5d or
--S(O).sub.2--C.sub.1-5 alkyl; Het.sup.1 represents a four- (e.g.
five-) to ten-membered heterocyclic group containing one to three
heteroatoms selected from oxygen, nitrogen and/or sulfur, which
group is optionally substituted by one or more (e.g. one to three)
substituents selected from halo, C.sub.1-3 alkyl, C.sub.1-3 alkoxy
and --C(O)--C.sub.1-4 alkyl; R.sup.5a, R.sup.5b and R.sup.5d
independently represent H, C.sub.1-5 alkyl, phenyl (which latter
group is optionally substituted by one or more substituents
selected from --OH, halo, cyano, pyrrolidin-1-yl, C.sub.1-4 alkyl
and C.sub.1-5 alkoxy (which latter group is optionally substituted
by one or more halo (e.g. fluoro) atoms)) or Het.sup.3; R.sup.5c
represents H or C.sub.1-5 alkyl (optionally substituted by phenyl
or phenoxy, which latter two groups are optionally substituted by
one to three substituents selected from halo, cyano and C.sub.1-2
alkyl); Het.sup.3 represents a five- to ten-membered heterocyclic
group containing one or two heteroatoms selected from oxygen and
nitrogen, which group is optionally substituted by one or more
substituents selected from oxo, C.sub.1-2 alkyl and
--C(O)--C.sub.1-4 alkyl; R.sup.6 represents H, C.sub.1-4 alkyl,
phenyl (which latter group is optionally substituted by one or more
cyano groups), --C(O)O--C.sub.1-5 alkyl,
--C(O)N(R.sup.10c)R.sup.10d or --S(O).sub.2R.sup.10e; R.sup.10c and
R.sup.10d independently represent H or C.sub.1-3 alkyl; R.sup.10e
represents C.sub.1-5 alkyl (optionally substituted by one or more
fluoro atoms) or phenyl (optionally substituted by one or more
substituents selected from halo, C.sub.1-3 alkyl and C.sub.1-3
alkoxy); R.sup.7 represents C.sub.1-5 alkyl optionally substituted
by Het.sup.4; Het.sup.4 represents a five- to ten-membered
heterocyclic group containing one or two heteroatoms selected from
oxygen and nitrogen, which group is optionally substituted by one
or more substituents selected from C.sub.1-2 alkyl and
--C(O)--C.sub.1-4 alkyl; R.sup.8a and R.sup.8b independently
represent H, C.sub.1-5 alkyl or -D-(phenyl), the phenyl part of
which latter group is optionally substituted by one or more (e.g.
one to three) substituents selected from halo, C.sub.1-3 alkyl and
C.sub.1-3 alkoxy; D represents C.sub.1-3 alkylene (e.g. CH.sub.2 or
C(CH.sub.3).sub.2); R.sup.2 represents --S(O).sub.2R.sup.3a or
--C(O)N(R.sup.3d)R.sup.3e; R.sup.3a represents C.sub.1-4 alkyl
(optionally substituted by phenyl or one or more halo (e.g. fluoro)
atoms), phenyl (which latter group is optionally substituted by or
more (e.g. one to three) substituents selected from halo, C.sub.1-3
alkyl and C.sub.1-3 alkoxy) or Het.sup.9; Het.sup.9 represents a
five- to ten-membered heterocyclic group containing one to three
heteroatoms selected from oxygen, nitrogen and/or sulfur, which
group is optionally substituted by one to three substituents
selected from halo, C.sub.1-2 alkyl and C.sub.1-2 alkoxy; R.sup.3d
and R.sup.3e independently represent H or C.sub.1-3 alkyl (which
latter group is by phenyl or one or more halo (e.g. fluoro) atoms),
phenyl (which latter group is optionally substituted by or more
(e.g. one to three) substituents selected from halo, C.sub.1-3
alkyl and C.sub.1-3 alkoxy); A represents C.sub.2 n-alkylene or
C.sub.3 n-alkylene, which latter group is optionally substituted,
in the 2-position relative to the point of attachment to the
oxabispidine N-atom, by --OH; B represents -Z.sup.1-,
-Z.sup.2-N(H)--, -Z.sup.2-C(O)N(R.sup.19b)--, -Z.sup.2-S(O).sub.2--
or -Z.sup.2-O-- (in which latter four groups, Z.sup.2 is attached
to the nitrogen atom bearing R.sup.2); Z.sup.1 represents C.sub.1-4
alkylene; Z.sup.2 represents C.sub.2-3 alkylene; R.sup.19b,
together with a single R.sup.4 substituent at a position on the
phenyl or pyridyl group that is ortho- to the position at which the
group B is attached, represents C.sub.2-3 alkylene; G represents
CH; R.sup.4 is absent (i.e. represents H) or represents one or two
cyano groups in the ortho- and/or, particularly, the para-position
relative to the point of attachment of the group B, or
alternatively, when B represents -Z.sup.2-C(O)N(R.sup.19b)--,
[0031] (i) an R.sup.4 substituent in a position on the phenyl or
pyridyl group that is ortho- to the position at which the group B
is attached may, together with R.sup.19b, represent C.sub.2-3
alkylene, and [0032] (ii) R.sup.4 may further represent a nitro
group in the para-position relative to the point of attachment of
the group B.
[0033] Particular compounds of the invention include, for example,
compounds of the Formula I, or pharmaceutically-acceptable salts
thereof, wherein, unless otherwise stated, each of each variable
group has any of the meanings defined hereinbefore or in paragraphs
(a) to (d) hereinafter:-- [0034] (a) R.sup.1 represents a
C.sub.1-C.sub.5 alkyl group, (such as methyl, ethyl, propyl, butyl,
propyl or pentyl), which is optionally substituted by a group
selected from phenyl, 2-cyanophenyl, 4-cyanophenyl,
2,4-dicyanophenyl, 2,6-dimethylphenyl, 3-methoxyphenyl,
4-methoxyphenyl, 4-acetylphenyl, 2-fluorophenyl, 3-fluorophenyl,
4-fluorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 3-pyridine,
4-pyridine, 2-chloro-3-pyridine, 6-methoxy-3-pyridine,
2,6-dichloro-4-pyridine, 4,5-dimethyl-2-furane,
3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-chlorophenyl,
4-(difluoromethoxy)phenyl, 4-(methylsulfonyl)phenyl,
2,5-dichlorophenyl, 3,5-dimethyl-4-isoxazole,
2,4-dimethyl-5-(1,3-thiazole), (1-methyl-2-(1H-imidazole),
2,6-dimethylphenyl, 4-tert-butylphenyl, or
2-fluoro-4-(trifluoromethyl)phenyl; and/or optionally interrupted
or terminated by an oxygen atom; [0035] (b) R.sup.41 to R.sup.46
are hydrogen; [0036] (c) R.sup.2 represents methylsulfonyl,
aminocarbonyl, N,N-dimethylaminocarbonyl, phenylsulfonyl,
ethylsulfonyl, N-methylaminocarbonyl, trifluoromethylsulfonyl,
acetyl, or isopropylsulfonyl; [0037] (d) the group
##STR00003##
[0037] represents phenyl, 2-cyanophenyl, 3-cyanophenyl,
4-cyanophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl,
4-(difluoromethoxy)phenyl, 2-chlorophenyl, 3-chlorophenyl, or
4-chlorophenyl.
[0038] Particularly preferred compounds of the invention include
those in which:
R.sup.1 represents straight- or branched-chain or part
cyclic/acyclic C.sub.1-6 alkyl, which alkyl group is optionally
interrupted by oxygen and/or substituted by: (i) one or more halo
or OR.sup.5b groups; and/or (ii) one group selected from phenyl
(which latter group is optionally substituted by one or more (e.g.
one to three) substituents selected from halo, cyano, C.sub.1-4
alkyl (e.g. methyl or C.sub.4 alkyl such as tert-butyl), C.sub.1-2
alkoxy (which C.sub.1-4 alkyl and C.sub.1-2 alkoxy groups are
optionally substituted by one or more halo (e.g. fluoro) atoms),
--C(O)--C.sub.1-2 alkyl and --S(O).sub.2--C.sub.1-2 alkyl),
Het.sup.1, --C(O)R.sup.5a, --N(R.sup.6)R.sup.5c, --C(O)N(H)R.sup.8a
and --S(O).sub.2--C.sub.1-4 alkyl; Het.sup.1 represents a five- or
six-membered heterocyclic group containing one or two heteroatoms
selected from oxygen, nitrogen and/or sulfur, which group is
optionally substituted by one or more (e.g. one or two)
substituents selected from halo (e.g. chloro), C.sub.1-2 alkyl and
C.sub.1-2 alkoxy; R.sup.5a and R.sup.5b independently represent
phenyl optionally substituted by one to three substituents selected
from halo, C.sub.1-2 alkyl and C.sub.1-2 alkoxy; R.sup.5c
represents C.sub.1-3 alkyl substituted by phenyl or phenoxy (which
latter two groups are optionally substituted by one or two cyano
groups); R.sup.6 represents H, C.sub.1-4 alkyl, --C(O)O--C.sub.1-5
alkyl --C(O)N(R.sup.10c)R.sup.10d or --S(O).sub.2R.sup.10e;
R.sup.10c and R.sup.10d independently represent H or C.sub.1-2
alkyl (e.g. methyl); R.sup.10e represents C.sub.1-3 alkyl
(optionally substituted by one or more fluoro atoms); R.sup.8a
represents C.sub.1-4 alkyl (e.g. tert-butyl) or -D-(phenyl);
R.sup.2 represents --S(O).sub.2R.sup.3a or
--C(O)N(R.sup.3d)R.sup.3e; R.sup.3a represents C.sub.1-2 alkyl
(optionally substituted by phenyl or one or more halo (e.g. fluoro)
atoms); R.sup.3d and R.sup.3e independently represent H or
C.sub.1-2 alkyl (e.g. methyl); A represents C.sub.2 or C.sub.3
n-alkylene; B represents -Z.sup.1- or -Z.sup.2-O-- (in which latter
group Z.sup.2 is attached to the nitrogen atom bearing R.sup.2);
Z.sup.1 represents C.sub.1-3 alkylene; Z.sup.2 represents C.sub.2-3
n-alkylene (e.g. C.sub.2 n-alkylene); R.sup.4 is absent (i.e.
represents H) or represents a cyano group in the para-position
relative to the point of attachment of the group B.
[0039] Especially preferred compounds of the invention include
those in which:
R.sup.1 represents straight- or branched-chain C.sub.1-3 alkyl
substituted by OR.sup.5b, phenyl (which latter group is optionally
substituted by one or two substituents selected from halo (e.g.
fluoro or chloro), cyano, tert-butyl, methyl, methoxy (which latter
two groups are optionally substituted by one to three fluoro
atoms), --C(O)CH.sub.3 and --S(O).sub.2CH.sub.3), Het.sup.1,
C(O)R.sup.5a, --N(R.sup.6)R.sup.5c, --N(H)C.sub.3-4 alkyl or
--C(O)N(H)R.sup.8a; Het.sup.1 represents an aromatic five- or
six-membered heterocyclic group containing one or two heteroatoms
selected from oxygen, nitrogen and/or sulfur, which group is
optionally substituted by one or two substituents selected from
chloro, methyl and methoxy; R.sup.5a and R.sup.5b independently
represent phenyl optionally substituted by one or two methyl or
methoxy groups; R.sup.5c represents H or benzyl; R.sup.6 represents
--C(O)O--C.sub.3-4 alkyl, --C(O)N(R.sup.10c)R.sup.10d or
--S(O).sub.2CH.sub.3; R.sup.10c and R.sup.10d independently
represent methyl or, preferably, H; R.sup.8a represents tert-butyl,
CH.sub.2-phenyl or C(CH.sub.3).sub.2-phenyl; R.sup.2 represents
--C(O)N(CH.sub.3).sub.2, --C(O)N(H)CH.sub.3, --C(O)NH.sub.2, or,
particularly, --S(O).sub.2CH.sub.3; A represents
--(CH.sub.2).sub.2--; B represents --(CH.sub.2).sub.1-3-- (e.g.
--CH.sub.2-- or --(CH.sub.2).sub.3--) or --(CH.sub.2).sub.2--O--
(in which latter group, the --(CH.sub.2).sub.2-- part is attached
to the nitrogen atom bearing R.sup.2).
[0040] Preferred compounds of the invention include the compounds
of the Examples disclosed hereinafter. In this respect, preferred
compounds of the invention that might be mentioned include: [0041]
(i)
tert-butyl[2-(7-{2-[[2-(4-cyanophenoxy)ethyl](methylsulfonyl)-amino]ethyl-
}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-carbamate; [0042]
(ii) tert-butyl
{2-[7-(2-{(aminocarbonyl)[2-(4-cyanophenoxy)ethyl]-amino}ethyl)-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl]ethyl}-carbamate; [0043] (iii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-methoxyphenyl)-2-oxoethyl]-9-ox-
a-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0044]
(iv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-methoxyphenyl)-2-oxoethyl]-9-ox-
a-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0045] (v)
N-[2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[2-(4-cyano-
phenoxy)ethyl]methanesulfonamide; [0046] (vi)
N-[2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[2-(4-cyano-
phenoxy)ethyl]urea; [0047] (vii)
2-[7-(2-{(aminocarbonyl)[2-(4-cyanophenoxy)ethyl]amino}ethyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl]-N-(tert-butyl)acetamide; [0048] (viii)
2-[7-(2-{(aminocarbonyl)[2-(4-cyanophenoxy)ethyl]amino}ethyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl]-N-benzylacetamide; [0049] (ix)
2-[7-(2-{(aminocarbonyl)[2-(4-cyanophenoxy)ethyl]amino}ethyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl]-N-(1-methyl-1-phenylethyl)acetamide;
[0050] (x) N-(tert-butyl)-2-(7-{2-[[2-(4-cyanophenoxy)ethyl]
(methylsulfonyl)-amino]ethyl}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)aceta-
mide; [0051] (xi)
N-benzyl-2-(7-{2-[[2-(4-cyanophenoxy)ethyl](methylsulfonyl)-amino]ethyl}--
9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)acetamide; [0052] (xii)
2-(7-{2-[[2-(4-cyanophenoxy)ethyl](methylsulfonyl)amino]ethyl}-9-oxa-3,7--
diazabicyclo[3.3.1]non-3-yl)-N-(1-methyl-1-phenyl-ethyl)acetamide;
[0053] (xiii)
tert-butyl[2-(7-{2-[[3-(4-cyanophenyl)propyl](methylsulfonyl)-amin-
o]ethyl}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-carbamate;
[0054] (xiv)
N-(tert-butyl)-2-(7-{2-[[3-(4-cyanophenyl)propyl](methylsulfonyl)-a-
mino]ethyl}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)acetamide; [0055]
(xv)
N-[2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[3-(4-cyano-
phenyl)propyl]methanesulfonamide; [0056] (xvi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(2,6-dimethylphenoxy)-ethyl]-9-oxa-
-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0057] (xvii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-di-
azabicyclo[3.3.1]non-3-yl}ethyl)urea; [0058] (xviii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-methoxyphenyl)ethyl]-9-oxa-3,7--
diazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0059] (xix)
N-(2-{7-[2-(4-acetylphenyl)ethyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}-
ethyl)-N-[2-(4-cyanophenoxy)ethyl]urea; [0060] (xx)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2-phenylethyl)-9-oxa-3,7-diazabicycl-
o[3.3.1]non-3-yl]ethyl}urea; [0061] (xxi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(3-fluorophenyl)ethyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0062] (xxii)
N-(2-{7-[(2-chloropyridin-3-yl)methyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non--
3-yl}ethyl)-N-[2-(4-cyanophenoxy)ethyl]methane-sulfonamide; [0063]
(xxiii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(6-methoxypyridin-3-yl)methyl]-9-oxa-
-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0064]
(xxiv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(4,5-dimethyl-2-furyl)-methyl]-9-oxa-
-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0065]
(xxv)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(4-fluorobenzyl)-9-oxa-3,7-diazabicyc-
lo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0066] (xxvi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(trifluoromethyl)benzyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0067]
(xxvii)
N-{2-[7-(4-chlorobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[-
2-(4-cyanophenoxy)ethyl]methanesulfonamide; [0068] (xxviii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(difluoromethoxy)-benzyl]-9-oxa-3,-
7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0069]
(xxix)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(methylsulfonyl)benzyl]-9-oxa-3,7--
diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0070] (xxx)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2-fluorobenzyl)-9-oxa-3,7-diazabicyc-
lo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0071] (xxxi)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2,4-difluorobenzyl)-9-oxa-3,7-diazab-
icyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0072] (xxxii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2,5-dichlorobenzyl)-9-oxa-3,7-diazab-
icyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0073] (xxxiii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[3-(trifluoromethyl)benzyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0074]
(xxxiv)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[2-
-(4-cyanophenoxy)ethyl]methanesulfonamide; [0075] (xxxv)
N-{2-[7-(2-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[2-
-(4-cyanophenoxy)ethyl]methanesulfonamide; [0076] (xxxvi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(2,6-dichloropyridin-4-yl)methyl]-9--
oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0077] (xxxvii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(pyridin-4-ylmethyl)-9-oxa-3-
,7-diazabicyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0078]
(xxxviii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(pyridin-3-ylmethyl)-9-oxa-3,7-diazab-
icyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0079] (xxxix)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(3,5-dimethylisoxazol-4-yl)methyl]-9-
-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0080] (xl)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(2,4-dimethyl-1,3-thiazol-5-yl)methy-
l]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0081] (xli)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(1-methyl-1H-imidazol-2-yl)met-
hyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0082] (xlii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}methanesulfonamide; [0083] (xliii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(3-phenylpropyl)-9-oxa-3,7-diazabicyc-
lo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0084] (xliv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[3-(4-cyanophenyl)propyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0085] (xlv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[3-(3-methoxyphenyl)propyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0086]
(xlvi)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2,6-dimethylbenzyl)-9-oxa-3,7-diazab-
icyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0087] (xlvii)
N-{2-[7-(4-tert-butylbenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-
-N-[2-(4-cyanophenoxy)ethyl]methanesulfonamide; [0088] (xlviii)
N-[2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[2-(4-cyano-
phenoxy)ethyl]-N',N'-dimethylurea; [0089] (xlix)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[2-
-(4-cyanophenoxy)ethyl]-N',N'-dimethylurea; [0090] (l)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-fluoro-4-(trifluoromethyl)benzyl]--
9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea;
[0091] (li)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(4-fluorobenzyl)-9-oxa-3,7-diaza-
bicyclo[3.3.1]non-3-yl]ethyl}-N',N'-dimethylurea; [0092] (lii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(difluoromethoxy)-benzyl]-9-oxa-3,-
7-diazabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea; [0093]
(liii)
N-[2-(4-cyanophenoxy)ethyl]-N',N'-dimethyl-N-{2-[7-(2-phenylethyl)-9-oxa--
3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}urea; [0094] (liv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-di-
azabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea; [0095] (lv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(3-fluorophenyl)ethyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea; [0096] (lvi)
N-[2-(4-cyanophenoxy)ethyl]-N',N'-dimethyl-N-{2-[7-(3-phenylpropyl)-9-oxa-
-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}urea; [0097] (lvii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2-phenylethyl)-9-oxa-3,7-diazabicycl-
o[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0098] (lviii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-di-
azabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0099] (lix)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-fluorophenyl)ethyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0100] (lx)
N-benzyl-N-(2-{7-[2-(4-cyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]n-
on-3-yl}ethyl)methanesulfonamide; [0101] (lxi)
N-(2-{7-[2-(4-cyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}-
ethyl)-N-(2-phenylethyl)methanesulfonamide; [0102] (lxii)
N-(2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl-
}ethyl)-N-(2-phenylethyl)methanesulfonamide; [0103] (lxiii)
N-(2-{7-[2-(4-cyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}-
ethyl)-N-(2-phenoxyethyl)methanesulfonamide; [0104] (lxiv)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(2-
-phenoxyethyl)methanesulfonamide; [0105] (lxv)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(2-
-phenylethyl)methanesulfonamide; [0106] (lxvi)
N-(2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl-
}ethyl)-N-(2-phenoxyethyl)methanesulfonamide; [0107] (lxvii)
N-benzyl-N-{2-[7-(4-fluorobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]-
ethyl}methanesulfonamide; [0108] (lxviii)
N-benzyl-N-{2-[7-(4-chlorobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]-
ethyl}methanesulfonamide; [0109] (lxix)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}benzenesulfonamide; [0110] (lxx)
N-(4-cyanobenzyl)-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]no-
n-3-yl]ethyl}methanesulfonamide; [0111] (lxxi)
N-(2-cyanobenzyl)-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]no-
n-3-yl]ethyl}methanesulfonamide; [0112] (lxxii)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(4-
-fluorobenzyl)methanesulfonamide; [0113] (lxxiii)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(3-
-fluorobenzyl)methanesulfonamide; [0114] (lxxiv)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[4-
-(difluoromethoxy)benzyl]methanesulfonamide; [0115] (lxxv)
N-(4-chlorobenzyl)-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]n-
on-3-yl]ethyl}methanesulfonamide; [0116] (lxxvi)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}ethanesulfonamide; [0117] (lxxvii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}-N'-methylurea; [0118] (lxxviii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}-N',N'-dimethylurea; [0119] (lxxix)
N-benzyl-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]no-
n-3-yl}ethyl)methanesulfonamide; [0120] (lxxx)
N-benzyl-N-(2-{7-[2-(2,4-dicyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3-
.1]non-3-yl}ethyl)methanesulfonamide; [0121] (lxxxi)
N-benzyl-N-(2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]-
non-3-yl}ethyl)methanesulfonamide; [0122] (lxxxii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}-1,1,1-trifluoromethanesulfonamide; [0123] (lxxxiii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}acetamide; [0124] (lxxxiv)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}urea; [0125] (lxxxv)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}propane-2-sulfonamide; and [0126] (lxxxvi)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(4-
-fluorobenzyl)urea; or a pharmaceutically acceptable derivative
thereof.
Preparation
[0127] According to the invention there is also provided a process
for the preparation of compounds of formula I which comprises:
(a) reaction of a compound of formula II,
##STR00004##
wherein R.sup.2, R.sup.4, R.sup.41 to R.sup.46, A, B and G are as
hereinbefore defined, with a compound of formula III,
R.sup.1-L.sup.1 III
wherein L.sup.1 represents a leaving group such as halo,
alkanesulfonate, perfluoroalkanesulfonate, arenesulfonate,
--OC(O)XR.sup.7, imidazole or R.sup.23O-- (wherein R.sup.23
represents, for example, C.sub.1-10 alkyl or aryl, which groups are
optionally substituted by one or more halo or nitro groups) and X,
R.sup.1 and R.sup.7 are as hereinbefore defined, for example at
between room and reflux temperature in the presence of a suitable
base (e.g. triethylamine, potassium carbonate or a bicarbonate,
such as sodium bicarbonate) and an appropriate solvent (e.g.
dichloromethane, chloroform, acetonitrile, N,N-dimethylformamide,
THF, toluene, water, a lower alkyl alcohol (e.g. ethanol) or
mixtures thereof); (b) for compounds of formula I in which R.sup.1
represents --C(O)XR.sup.7 or --C(O)N(R.sup.8a)R.sup.5d, reaction of
a compound of formula IV,
##STR00005##
wherein R.sup.2, R.sup.4, R.sup.41 to R.sup.46, A, B, G and L.sup.1
are as hereinbefore defined, with a compound of formula V,
R.sup.24--H V
wherein R.sup.24 represents --XR.sup.7 or --N(R.sup.8a)R.sup.5d and
R.sup.5d, R.sup.7, R.sup.8a and X are as hereinbefore defined, for
example under similar conditions to those described hereinbefore
(process step (a)); (c) for compounds in which R.sup.1 represents
--C(O)N(H)R.sup.8a, reaction of a compound of formula II, as
hereinbefore defined, with a compound of formula VI,
R.sup.8a--N.dbd.C.dbd.O VI
wherein R.sup.8a is as hereinbefore defined, for example at between
0.degree. C. and reflux temperature in the presence of an
appropriate organic solvent (e.g. dichloromethane), or via solid
phase synthesis under conditions known to those skilled in the art;
(d) reaction of a compound of formula VII,
##STR00006##
wherein R.sup.1 and R.sup.41 to R.sup.46 are as hereinbefore
defined, with a compound of formula VIII,
##STR00007##
wherein L.sup.2 represents a leaving group such as halo,
alkanesulfonate (e.g. mesylate), perfluoroalkanesulfonate or
arenesulfonate (e.g. benzenesulfonate, 2- or
4-nitrobenzenesulfonate or, particularly, toluenesulfonate) and
R.sup.2, R.sup.4, A, B and G are as hereinbefore defined, for
example at elevated temperature (e.g. between 35.degree. C. and
reflux temperature) in the presence of a suitable base (e.g.
triethylamine or potassium carbonate) and an appropriate organic
solvent (e.g. acetonitrile, dichloromethane, chloroform,
dimethylsulfoxide, N,N-dimethylformamide, a lower alkyl alcohol
(e.g. ethanol), isopropyl acetate or mixtures thereof); (e) for
compounds of formula I in which A represents C.sub.3-6 alkylene
substituted in the 2-position (relative to the oxabispidine N-atom)
by --OH or amino, reaction of a compound of formula VII, as
hereinbefore defined, with a compound of formula IX,
##STR00008##
or a protected derivative thereof, wherein Y represents O or NH and
R.sup.2, R.sup.4, B and G are as hereinbefore defined, for example
at elevated temperature (e.g. 60.degree. C. to reflux) in the
presence of a suitable solvent (e.g. a lower alkyl alcohol (e.g.
IPA), acetonitrile, or a mixture of a lower alkyl alcohol and
water); (f) for compounds of formula I in which B represents
-Z.sup.2-O--, reaction of a compound of formula X,
##STR00009##
wherein R.sup.1, R.sup.2, R.sup.41 to R.sup.46, A and Z.sup.2 are
as hereinbefore defined, with a compound of formula XI,
##STR00010##
wherein R.sup.4 and G are as hereinbefore defined, for example
under Mitsunobu-type conditions e.g. at between ambient (e.g.
25.degree. C.) and reflux temperature in the presence of a tertiary
phosphine (e.g. tributylphosphine or triphenylphosphine), an
azodicarboxylate derivative (e.g. diethylazodicarboxylate or
1,1'-(azodicarbonyl)dipiperidine) and an appropriate organic
solvent (e.g. dichloromethane or toluene); (g) for compounds of
formula I in which G represents N and B represents -Z.sup.2-O--,
reaction of a compound of formula X, as hereinbefore defined, with
a compound of formula XII,
##STR00011##
wherein R.sup.4 and L.sup.2 are as hereinbefore defined, for
example at between 10.degree. C. and reflux temperature in the
presence of a suitable base (e.g. sodium hydride) and an
appropriate solvent (e.g. N,N-dimethylformamide); (h) for compounds
of formula I in which B is as hereinbefore defined, except that it
does not represent a direct bond, reaction of a compound of formula
XIII,
##STR00012##
wherein R.sup.1, R.sup.2, R.sup.41 to R.sup.46 and A are as
hereinbefore defined, with a compound of formula XIV,
##STR00013##
wherein B.sup.a represents B as hereinbefore defined, except that
it does not represent a direct bond, and R.sup.4, G, and L.sup.2
are as hereinbefore defined, for example at elevated temperature
(e.g. between 35.degree. C. and reflux temperature) in the presence
of a suitable base (e.g. triethylamine or potassium carbonate) and
an appropriate organic solvent (e.g. acetonitrile, dichloromethane,
chloroform, dimethylsulfoxide, N,N-dimethylformamide, a lower alkyl
alcohol (e.g. ethanol), isopropyl acetate or mixtures thereof); (i)
reaction of a compound of formula XV,
##STR00014##
wherein R.sup.1, R.sup.4, R.sup.41 to R.sup.46, A, B and G are as
hereinbefore defined, with a compound of formula XVI,
R.sup.2-L.sup.3 XI
wherein L.sup.3 represents a suitable leaving group (such as halo,
--OS(O).sub.2R.sup.3a, --OC(O)OR.sup.3b, --OC(O)R.sup.3c or
--NH.sub.2), and R.sup.2 is as hereinbefore defined, for example
under conditions known to those skilled in the art (such as: (1)
when R.sup.2 represents --S(O).sub.2R.sup.3a,
--C(O)N(R.sup.3d)(R.sup.3e) or S(O).sub.2N(R.sup.3f)(R.sup.3g) and
L.sup.3 represents halo or --OS(O).sub.2R.sup.3a, reaction at
between sub-ambient temperature (e.g. 0 to 10.degree. C.) and
ambient temperature (e.g. 20 to 30.degree. C.) in the presence of a
suitable base (e.g. triethylamine) and an appropriate solvent (e.g.
DCM); and (2) when R.sup.2 represents --C(O)N(R.sup.3d)(R.sup.3e)
and L.sup.3 represents --N(R.sup.3d)(R.sup.3e), reaction at
elevated temperature (e.g. 110 to 150.degree. C., such as
130.degree. C.)); (j) for compounds of formula I in which R.sup.2
represents --C(O)N(H)R.sup.3d, reaction of a compound of formula
XV, as hereinbefore defined, with a compound of formula XVII
O.dbd.C.dbd.N--R XVII
wherein R represents a monovalent metal cation (e.g. an alkali
metal cation, such as a potassium ion) or R represents R.sup.3d as
hereinbefore defined, except that it does not represent H, for
example under conditions known to those skilled in the art (such as
when R represents a potassium ion, reaction at ambient temperature
(e.g. 15 to 30.degree. C.) in the presence of a suitable acid (e.g.
acetic acid) and an appropriate solvent (e.g. 1,4-dioxane, water,
or a mixture thereof); (k) for compounds of formula I in which
R.sup.1 represents C.sub.1-12 alkyl substituted by one or more
substituents as defined above in respect of R.sup.1, which
substituent(s) is/include a --N(R.sup.9b)S(O).sub.2R.sup.9d group,
reaction of a compound of formula XVII,
##STR00015##
wherein R.sup.1a represents C.sub.1-12 alkylene, which group is
optionally substituted by one or more substituents as defined above
in respect of R.sup.1, and R.sup.2, R.sup.4, R.sup.9b, R.sup.41 to
R.sup.46, A, B and G are as hereinbefore defined, with a compound
of formula XIX,
L.sup.2-S(O).sub.2R.sup.9d XIX
wherein R.sup.9d and L.sup.2 are as hereinbefore defined, for
example under conditions that are know to those skilled in the art
(e.g. at ambient temperature (such as from 15 to 30.degree. C.) in
the presence of a suitable base (such as such as triethylamine,
potassium carbonate or sodium hydrogencarbonate) and an appropriate
solvent (such as DCM, CHCl.sub.3, acetonitrile, DMF, THF, toluene,
or mixtures thereof); (l) for compounds of formula I in which
R.sup.1 represents C.sub.1-12 alkyl substituted by one or more
substituents as defined above in respect of R.sup.1, which
substituent(s) is/include a --S(O).sub.2N(R.sup.9b)R.sup.9c or
--N(R.sup.9b)S(O).sub.2R.sup.9d group, reaction of a compound of
formula II, as hereinbefore defined, with a compound of formula
XIXA or XIXB,
L.sup.1-R.sup.1a--SO.sub.2--N(R.sup.9b)R.sup.9c XIXA
L.sup.1-R.sup.1a--N(R.sup.9b)--SO.sub.2--R.sup.9d XIXB
wherein L.sup.1, R.sup.1a, R.sup.9b, R.sup.9c and R.sup.9d are as
hereinbefore defined, for example under conditions that are know to
those skilled in the art (e.g. at ambient temperature to reflux in
the presence of a suitable base (such as such as triethylamine,
potassium carbonate or sodium hydrogencarbonate) and an appropriate
solvent (such as DCM, CHCl.sub.3, acetonitrile, DMF, THF, toluene,
or mixtures thereof); (m) for compounds of formula I in which
R.sup.1 represents --C(O)XR.sup.7, --C(O)N(R.sup.8a)R.sup.5d or
--S(O).sub.2R.sup.9a, reaction of a compound of formula XX,
##STR00016##
wherein R.sup.1a represents --C(O)XR.sup.7,
--C(O)N(R.sup.8a)R.sup.5d or --S(O).sub.2R.sup.9a and R.sup.5d,
R.sup.7, R.sup.8a, R.sup.9a, R.sup.41 to R.sup.46 and L.sup.2 are
as hereinbefore defined, with a compound of formula XXI,
##STR00017##
wherein R.sup.2, R.sup.4, A, B and G are as hereinbefore defined,
for example at between room and reflux temperature in the presence
of a suitable base (e.g. sodium hydrogencarbonate or potassium
carbonate) and an appropriate organic solvent (e.g. acetonitrile);
(n) for compounds of formula I which are oxabispidine-nitrogen
N-oxide derivatives, oxidation of the corresponding oxabispidine
nitrogen of a corresponding compound of formula I, in the presence
of a suitable oxidising agent (e.g. MCPBA), for example at
0.degree. C. in the presence of a suitable organic solvent (e.g.
dichloromethane); (o) for compounds of formula I which are
C.sub.1-4 alkyl quaternary ammonium salt derivatives, in which the
alkyl group is attached to a oxabispidine nitrogen, reaction, at
the oxabispidine nitrogen, of a corresponding compound of formula I
with a compound of formula XXII,
R.sup.25-L.sup.4 XXII
wherein R.sup.25 represents C.sub.1-4 alkyl and L.sup.4 is a
leaving group such as halo, alkanesulfonate or arenesulfonate, for
example at room temperature in the presence of an appropriate
organic solvent (e.g. N,N-dimethylformamide), followed by
purification (using e.g. HPLC) in the presence of a suitable
counter-ion provider (e.g. NH.sub.4OAc); (o) conversion of one
R.sup.4 substituent to another using techniques well known to those
skilled in the art; (p) introduction of one or more (further)
R.sup.4 substituents to the aromatic ring using techniques well
known to those skilled in the art (e.g. chlorination); (q) for
compounds of formula I in wherein R.sup.1 represents C.sub.1-12
alkylene, which group is optionally substituted by one or more
substituents as defined above in respect of R.sup.1, reaction of a
compound of formula II
##STR00018##
wherein R.sup.2, R.sup.4, R.sup.41 to R.sup.46, A, B and G are as
hereinbefore defined, with the appropriate aldehyde, for example
under conditions that are known to those skilled in the art (e.g.
at room temperature, such as from 15 to 30.degree. C.) in the
presence of a reducing agent (such as sodium cyanoborohydride,
sodium triacetoxyborohydride, or similar compounds) and an
appropriate solvent (such as 1,2-dichloroethane, dichloroethane,
methanol, ethanol or mixtures thereof); (r) reaction of a compound
with formula VII
##STR00019##
wherein R.sup.1 and R.sup.41 to R.sup.46 are as hereinbefore
defined, with a compound of formula XXIII
##STR00020##
wherein R.sup.2, R.sup.4, B and G are as hereinbefore defined, for
example under conditions that are known to those skilled in the art
(e.g. at room temperature, such as from 15 to 30.degree. C.) in the
presence of a reducing agent (such as sodium cyanoborohydride,
sodium triacetoxyborohydride, or similar hydride donating
compounds) and an appropriate solvent (such as 1,2-dichloroethane,
dichloroethane, methanol, ethanol or mixtures thereof); or (s)
deprotection of a protected derivative of a compound of formula I
as defined above.
[0128] Compounds of formulae II, IV, VII, VIII, IX, X, XIII, XV,
XVIII, XX and XXI may be prepared according to or by analogy with
the procedures described or referred to in WO 01/28992, WO
02/28863, WO 02/28864, WO 02/83690 and WO 02/83691, the disclosures
of which documents are hereby incorporated by reference.
[0129] Compounds of formulae III, V, VI, XI, XII, XIV, XVI, XVII,
XIX, XIXA, XIXB, XXII and derivatives thereof, are either
commercially available, are known in the literature, or may be
obtained either by analogy with the processes described herein, or
by conventional synthetic procedures, in accordance with standard
techniques, from readily available starting materials using
appropriate reagents and reaction conditions.
[0130] Substituents on the aryl (e.g. phenyl), and (if appropriate)
heterocyclic, group(s) in compounds defined herein may be converted
to other claimed substituents using techniques well known to those
skilled in the art. For example, hydroxy may be converted to
alkoxy, phenyl may be halogenated to give halophenyl, nitro may be
reduced to give amino, halo may be displaced by cyano, etc.
[0131] The skilled person will also appreciate that various
standard substituent or functional group interconversions and
transformations within certain compounds of formula I will provide
other compounds of formulae I. For example, carbonyl may be reduced
to hydroxy or alkylene, and hydroxy may be converted to halo.
[0132] The compounds of the invention may be isolated from their
reaction mixtures using conventional techniques.
[0133] It will be appreciated by those skilled in the art that, in
the process described above, the functional groups of intermediate
compounds may be, or may need to be, protected by protecting
groups.
[0134] Functional groups which it is desirable to protect include
hydroxy, amino and carboxylic acid. Suitable protecting groups for
hydroxy include trialkylsilyl and diarylalkylsilyl groups (e.g.
tert-butyldimethylsilyl, tert-butyldiphenylsilyl or
trimethylsilyl), tetrahydropyranyl and alkylcarbonyl groups (e.g.
methyl- and ethylcarbonyl groups). Suitable protecting groups for
amino include benzyl, sulfonamido (e.g. benzenesulfonamido),
tert-butyloxycarbonyl, 9-fluorenyl-methoxycarbonyl or
benzyloxycarbonyl. Suitable protecting groups for amidino and
guanidino include benzyloxycarbonyl. Suitable protecting groups for
carboxylic acid include C.sub.1-6 alkyl or benzyl esters.
[0135] The protection and deprotection of functional groups may
take place before or after any of the reaction steps described
hereinbefore. Protecting groups may be removed in accordance with
techniques which are well known to those skilled in the art and as
described hereinafter.
[0136] The use of protecting groups is fully described in
"Protective Groups in Organic Chemistry", edited by J. W. F.
McOmie, Plenum Press (1973), and "Protective Groups in Organic
Synthesis", 3.sup.rd edition, T. W. Greene & P. G. M. Wutz,
Wiley-Interscience (1999).
[0137] Persons skilled in the art will appreciate that, in order to
obtain compounds of the invention in an alternative, and, on some
occasions, more convenient, manner, the individual process steps
mentioned herein may be performed in a different order, and/or the
individual reactions may be performed at a different stage in the
overall route (i.e. substituents may be added to and/or chemical
transformations performed upon, different intermediates to those
associated hereinbefore with a particular reaction). This will
depend inter alia on factors such as the nature of other functional
groups present in a particular substrate, the availability of key
intermediates and the protecting group strategy (if any) to be
adopted. Clearly, the type of chemistry involved will influence the
choice of reagent that is used in the said synthetic steps, the
need, and type, of protecting groups that are employed, and the
sequence for accomplishing the synthesis.
[0138] It will also be appreciated by those skilled in the art
that, although certain protected derivatives of compounds of
formula I, which may be made prior to a final deprotection stage,
may not possess pharmacological activity as such, they may be
administered parenterally or orally and thereafter metabolised in
the body to form compounds of the invention which are
pharmacologically active. Such derivatives may therefore be
described as "prodrugs". Moreover, certain compounds of formula I
may act as prodrugs of other compounds of formula I.
[0139] All prodrugs of compounds of formula I are included within
the scope of the invention.
[0140] Some of the intermediates referred to hereinbefore are
novel. According to a further aspect of the invention there is thus
provided: (a) a compound of formula II, as hereinbefore defined, or
a protected derivative thereof; (b) a compound of formula IV, or a
protected derivative thereof; (c) a compound of formula VIII, or a
protected derivative thereof; (d) a compound of formula IX, or a
protected derivative thereof; (e) a compound of formula X, or a
protected derivative thereof; (f) a compound of formula XIII, or a
protected derivative thereof; (g) a compound of formula XV, or a
protected derivative thereof, provided that A is interrupted by
--S(O).sub.2N(R.sup.18a)-- or --N(R.sup.18b)S(O).sub.2-- and/or B
represents -Z.sup.1-[C(O)].sub.aC(H)(R.sup.19a)--,
-Z.sup.2-[C(O)].sub.cN(R.sup.19b)--,
-Z.sup.2-N(R.sup.18c)S(O).sub.2-- or
-Z.sup.2-S(O).sub.2N(R.sup.18d)--, wherein R.sup.19a is other than
H and R.sup.19b is other than H or C.sub.1-6 alkyl; (h) a compound
of formula XVIII, or a protected derivative thereof; and (i) a
compound of formula XXI, or a protected derivative thereof.
Medical and Pharmaceutical Use
[0141] Compounds of the invention are useful because they possess
pharmacological activity. They are therefore indicated as
pharmaceuticals.
[0142] Thus, according to a further aspect of the invention there
is provided the compounds of the invention for use as
pharmaceuticals.
[0143] In particular, the compounds of the invention exhibit
myocardial electrophysiological activity, for example as
demonstrated in the test described below.
[0144] The compounds of the invention are thus expected to be
useful in both the prophylaxis and the treatment of arrhythmias,
and in particular atrial and ventricular arrhythmias.
[0145] The compounds of the invention are thus indicated in the
treatment or prophylaxis of cardiac diseases, or in indications
related to cardiac diseases, in which arrhythmias are believed to
play a major role, including ischaemic heart disease, sudden heart
attack, myocardial infarction, heart failure, cardiac surgery and
thromboembolic events.
[0146] In the treatment of arrhythmias, compounds of the invention
have been found to selectively delay cardiac repolarization and
increase refractoriness.
[0147] According to a further aspect of the invention, there is
provided a method of treatment of an arrhythmia which method
comprises administration of a therapeutically effective amount of a
compound of the invention to a person suffering from, or
susceptible to, such a condition.
Pharmaceutical Preparations
[0148] The compounds of the invention will normally be administered
orally, subcutaneously, intravenously, intraarterially,
transdermally, intranasally, by inhalation, or by any other
parenteral route, in the form of pharmaceutical preparations
comprising the active ingredient either as a free base or a
non-toxic organic or inorganic acid addition salt, in a
pharmaceutically acceptable dosage form. Depending upon the
disorder and patient to be treated, as well as the route of
administration, the compositions may be administered at varying
doses.
[0149] The compounds of the invention may also be combined with any
other drugs useful in the treatment of arrhythmias and/or other
cardiovascular disorders. In particular the compounds of the
invention may be combined with an anti-coagulant.
[0150] When used herein, the term "an anticoagulant" includes
references to one a substance selected from the group consisting of
aspirin, warfarin, enoxaparin, heparin, low molecular weight
heparin, cilostazol, clopidogrel, ticlopidine, tirofiban,
abciximab, dipyridamole, plasma protein fraction, human albumin,
low molecular weight dextran, hetastarch, reteplase, alteplase,
streptokinase, urokinase, dalteparin, filgrastin, immunoglogulin,
ginkolide B, hirudins, foropafant, rocepafant, bivalirudin,
dermatan sulfate mediolanum, eptilibatide, tirofiban,
thrombomodulin, abcxmab, low molecular weight dermatan
sulfate-opocrin, eptacog alfa, argatroban, fondaparinux sodium,
tifacogin, lepirudin, desirudin, OP2000, roxifiban, parnaparin
sodium, human hemoglobin (Hemosol), bovine hemoglobin (Biopure),
human hemoglobin (Northfield), antithrombin III, RSR 13,
heparin-oral (Emisphere) transgenic antithrombin III, H37695,
enoxaparin sodium, mesoglycan, CTC 111, bivalirudin, and any
derivatives and/or combinations thereof.
[0151] Particular anticoagulants that may be mentioned include
aspirin and warfarin.
[0152] The term "an anticoagulant" also includes references to
thrombin inhibitors. Thrombin inhibitors that may be mentioned
include low molecular weight thrombin inhibitors. The term "low
molecular weight thrombin inhibitors" will be understood by those
skilled in the art, and includes references to any composition of
matter (e.g. chemical compound) that inhibits thrombin to an
experimentally determinable degree (as determined by in vivo and/or
in vitro tests), and which possesses a molecular weight of below
about 2,000, preferably below about 1,000.
[0153] Preferred low molecular weight thrombin inhibitors include
low molecular weight peptide-based, amino acid-based, and/or
peptide analogue-based, thrombin inhibitors, as well as derivatives
thereof.
[0154] The term "low molecular weight peptide-based, amino
acid-based, and/or peptide analogue-based, thrombin inhibitors"
will be well understood by one skilled in the art to include
references to low molecular weight thrombin inhibitors with one to
four peptide linkages, and includes those described in the review
paper by Claesson in Blood Coagul. Fibrin. 5, 411 (1994), as well
as those disclosed in
U.S. Pat. No. 4,346,078, International Patent Applications WO
93/11152, WO 93/18060, WO 93/05069, WO 94/20467, WO 94/29336, WO
95/35309, WO 95/23609, WO 96/03374, WO 96/06832, WO 96/06849, WO
96/25426, WO 96/32110, WO 97/01338, WO 97/02284, WO 97/15190, WO
97/30708, WO 97/40024, WO 97/46577, WO 98/06740, WO 97/49404, WO
97/11693, WO 97/24135, WO 97/47299, WO 98/01422, WO 98/57932, WO
99/29664, WO 98/06741, WO 99/37668, WO 99/37611, WO 98/37075, WO
99/00371, WO 99/28297, WO 99/29670, WO 99/40072, WO 99/54313, WO
96/31504, WO 00/01704 and WO 00/08014; and European Patent
Applications 648 780, 468 231, 559 046, 641 779, 185 390, 526 877,
542 525, 195 212, 362 002, 364 344, 530 167, 293 881, 686 642, 669
317, 601 459 and 623 596, the disclosures in all of which documents
are hereby incorporated by reference.
[0155] In the present application, derivatives of thrombin
inhibitors include chemical modifications, such as esters, prodrugs
and metabolites, whether active or inactive, and pharmaceutically
acceptable salts and solvates, such as hydrates, of any of these,
and solvates of any such salt.
[0156] Preferred low molecular weight peptide-based thrombin
inhibitors include those known collectively as the "gatrans".
Particular gatrans which may be mentioned include
HOOC--CH.sub.2--(R)Cha-Pic-Nag-H (known as inogatran) and
HOOC--CH.sub.2--(R)Cgl-Aze-Pab-H (known as melagatran) (see
International Patent Application WO 93/11152 and WO 94/29336,
respectively, and the lists of abbreviations contained
therein).
[0157] International Patent Application WO 97/23499 discloses a
number of compounds which have been found to be useful as prodrugs
of thrombin inhibitors. Said prodrugs have the general formula
R.sub.aOOC--CH.sub.2--(R)Cgl-Aze-Pab-R.sub.b
wherein R.sub.a represents H, benzyl or C.sub.1-10 alkyl, R.sup.b
(which replaces one of the hydrogen atoms in the amidino unit of
Pab-H) represents OH, OC(O)R.sub.c or C(O)OR.sub.d, R.sub.c
represents C.sub.1-17 alkyl, phenyl or 2-naphthyl and R.sub.d
represents C.sub.1-12 alkyl, phenyl, C.sub.1-3 alkylphenyl, or
2-naphthyl. Preferred compounds include
R.sub.aOOC--CH.sub.2--(R)Cgl-Aze-Pab-OH, wherein R.sub.a represents
benzyl or C.sub.1-10 alkyl, e.g. ethyl or isopropyl, especially
EtOOC--CH.sub.2--(R)Cgl-Aze-Pab-OH. The active thrombin inhibitors
themselves are disclosed in WO 94/29336.
[0158] According to a further aspect of the invention there is thus
provided a pharmaceutical formulation including a compound of the
invention in admixture with a pharmaceutically acceptable adjuvant,
diluent or carrier.
[0159] Suitable daily doses of the compounds of the invention in
therapeutic treatment of humans are about 0.005 to 50.0 mg/kg body
weight at oral administration and about 0.005 to 15.0 mg/kg body
weight at parenteral administration. Preferable ranges of daily
doses of the compounds of the invention in therapeutic treatment of
humans are about 0.005 to 20.0 mg/kg body weight at oral
administration and about 0.005 to 5.0 mg/kg body weight at
parenteral administration.
[0160] The compounds of the invention have the advantage that they
are effective against cardiac arrhythmias.
[0161] Compounds of the invention may also have the advantage that
they may be more efficacious than, be less toxic than, have a
broader range of activity (including exhibiting any combination of
class I, class II, class III and/or class IV activity (especially
class I and/or class IV activity in addition to class III
activity)) than, be more potent than, be longer acting than,
produce fewer side effects (including a lower incidence of
proarrhythmias such as torsades de pointes) than, be more easily
absorbed than, or that they may have other useful pharmacological
properties over, compounds known in the prior art.
Biological Tests
Test A
[0162] Primary Electrophysiological Effects In Anaesthetised Guinea
Pigs Guinea pigs weighing between 500 and 1000 g were used. The
animals were housed for at least one week before the experiment and
had free access to food and tap water during that period.
[0163] Anaesthesia was induced by an intraperitoneal injection of
pentobarbital (50 to 60 mg/kg) and catheters were introduced into
one carotid artery (for blood pressure recording and blood
sampling) and into one jugular vein (for drug infusions). Needle
electrodes were placed on the limbs for recording of ECGs (lead
II). A thermistor was placed in the rectum and the animal was
placed on a heating pad, set to a rectal temperature of between
37.5 and 38.5.degree. C.
[0164] A tracheotomy was performed and the animal was artificially
ventilated with room air by use of a small animal ventilator, set
to keep blood gases within the normal range for the species. In
order to reduce autonomic influences both vagi were cut in the
neck, and 0.5 mg/kg of propranolol was given intravenously, 15
minutes before the start of the experiment.
[0165] The left ventricular epicardium was exposed by a left-sided
thoracotomy, and a custom-designed suction electrode for recording
of the monophasic action potential (MAP) was applied to the left
ventricular free wall. The electrode was kept in position as long
as an acceptable signal could be recorded, otherwise it was moved
to a new position. A bipolar electrode for pacing was clipped to
the left atrium. Pacing (1 ms duration, twice the diastolic
threshold) was performed with a custom-made constant current
stimulator. The heart was paced at a frequency just above the
spontaneous sinus rate during 30 s every fifth minute throughout
the study.
[0166] The MAP signal, the blood pressure signal and the lead II
ECG were collected (the sampling frequency was 1000 Hz and each
sampling period 10 s) on a personal computer during the last 10 s
of each 30 s pacing sequence and the last 10 s of the following min
of sinus rhythm. The signals were processed using a custom-designed
computer program (PharmLab v 4.0).
[0167] The test procedure consisted of two basal control
recordings, 3 minutes apart, during both pacing and sinus rhythm.
After the second control recording, the first dose of the test
substance was infused in a volume of is 0.2 mL/kg into the jugular
vein catheter for 30 seconds. Three minutes later, pacing was
started and a new recording was made. Five minutes after the
previous dose, the next dose of test substance was administered.
Six to ten consecutive doses were given during each experiment.
Data Analysis
[0168] Of the numerous variables measured in this analysis, three
were selected as the most important for comparison and selection of
active compounds. The three variables selected were the MAP
duration at 75 percent repolarization during pacing, the
atrio-ventricular (AV) conduction time (defined as the interval
between the atrial pace pulse and the start of the ventricular MAP)
during pacing, and the heart rate (defined as the RR interval
during sinus rhythm). Systolic and diastolic blood pressure were
measured in order to judge the haemodynamic status of the
anaesthetised animal. Further, the ECG was checked for arrhythmias
and/or morphological changes.
[0169] The mean of the two control recordings was set to zero and
the effects recorded after consecutive doses of test substance were
expressed as percentage changes from this value. By plotting these
percentage values against the cumulative dose administered before
each recording, it was possible to construct dose-response curves.
In this way, each experiment generated three dose-response curves,
one for MAP duration, one for AV-conduction time and one for the
sinus frequency (RR interval). A mean curve of all experiments
performed with a test substance was calculated, and potency values
were derived from the mean curve. All dose-response curves in these
experiments were constructed by linear connection of the data
points obtained. The cumulative dose prolonging the MAP duration by
10% from the baseline was used as an index to assess the class III
electrophysiological potency of the agent under investigation
(D.sub.10).
Test B
Rb.sup.+-Efflux Assay for Detection of HERG Channel Blockers
[0170] The human ether-a-go-go related gene (HERG) encodes the
voltage-gated K.sup.+ channel underlying the cardiac rapid delayed
rectifier current I.sub.Kr. The IC50 value for HERG channel
blockade was determined using a high throughput functional assay
based on depolarisation-induced Rb.sup.+-efflux from Chinese
hamster ovary cells stably expressing the HERG-channel.
[0171] Cells were grown in Ham F12 (Life Technologies 31765-027)
supplemented with 10% FBS and 0.6 mg/mL hygromycin B and were
routinely passaged twice-weekly. For experimental studies, cells
were plated at a density of 15,000 cells/well in Falcon, 384-well
tissue culture-treated black-walled clear-bottomed plates and were
thereafter incubated overnight at 37.degree. C. in a cell culture
incubator.
[0172] Following incubating overnight, cell plates were washed and
a Rb.sup.+-Load buffer (a physiological buffer containing Rb.sup.+)
was added. Cell plates were then incubated for 3 hours and were
thereafter washed. Following this wash, the test compounds were
added. The cell plates were then incubated for another 10 minutes
and, following this incubation period, external K.sup.+
concentration was increased in order to depolarize the cells and
activate HERG channels. After a ten minute exposure period to the
increased K.sup.+ concentration, supernatants were transferred to
new microplates for subsequent determination of Rb.sup.+ content,
using Atomic Absorption Spectrometry analysis.
[0173] The basal Rb.sup.+ efflux (content of Rb.sup.+ (mg/L) in
supernatants of wells receiving only wash buffer) was defined as
100% inhibition and the stimulated Rb.sup.+ efflux (content of
Rb.sup.+ (mg/L) in supernatants of wells exposed only to increased
external potassium concentration) was defined as 0% inhibition.
[0174] Compound activity was expressed as:
100 .times. [ 1 - A - B C - B ] ##EQU00001##
A: Rb.sup.+ content in wells receiving test compound+increased
external K.sup.+. B: Basal Rb.sup.+ efflux. C: Stimulated Rb.sup.+
efflux.
[0175] The invention is illustrated by way of the following
examples.
EXAMPLES
General Experimental Procedures
[0176] Mass spectra were recorded on one of the following
instruments: MUX(8)-LCT, ZQ Masspectrometer and Quattro micro, all
from Waters Micromass.
LC-MS:
[0177] Separation was performed using Agilent 1100 Series Modules
or Waters 1525 pump on a ACT (Advanced Chromatography Technologies)
ACE C8-3.times.50 mm 3 .mu.m with gradient elution.
[0178] Samples were injected using Waters 2700 Sample Manager.
Mobile Phases:
[0179] Generic gradients were applied from 5% to 95%
acetonitrile.
[0180] Buffers containing 10 mM ammonium acetate or 5 mM ammonium
formate/5 mM formic acid were used.
[0181] The mass spectra were recorded with a Waters ZQ2000 or
Waters ZMD equipped with an electrospray interface, switching
positive and negative ionization mode. UV spectra were collected by
a Agilent 1100 PDA or Waters 2996 DAD and the evaporative light
scattering (ELS) signal by a Sedere Sedex 55 or 75.
[0182] Data collection and evaluation were performed using the
MassLynx software.
[0183] .sup.1H NMR and .sup.13C NMR measurements were performed on
a BRUKER ACP 300 and Varian 300, 400, 500 and 600 Mercury, Unity
plus and Inova spectrometers, operating at .sup.1H frequencies of
300, 400, 500 and 600 MHz respectively and at .sup.13C frequencies
of 75.4, 100.6, 125.7 and 150.9 MHz respectively.
[0184] Rotamers may or may not be denoted in spectra depending upon
ease of interpretation of spectra. Unless otherwise stated,
chemical shifts are given in ppm with the solvent as internal
standard.
Synthesis of Intermediates
[0185] The following intermediates were not commercially available,
and were therefore prepared by the methods described below.
Preparation A
Methanesulfonic acid
2-{[3-(4-cyanophenyl)propyl]methanesulfonylamino}ethyl ester
(i) 3-(4-Cyanophenyl)acrylic acid ethyl ester
[0186] To a solution of 4-bromobenzonitrile (50 g, 0.275 mol) and
ethyl acrylate (35.4 g, 0.412 mol) in dry DMF (250 mL), palladium
acetate (0.61 g, 0.0027 mol), tris-o-tolylphosphine (3.34 g, 0.011
mol) and triethylamine (57.3 mL, 0.412 mol) were added and refluxed
at 95-100.degree. C. for 2 h under an argon atmosphere. The
reaction was quenched by adding water (250 mL) and extracted with
ether (3.times.250 mL). The combined extract was washed with 1.5 N
HCl (250 mL), water and brine and dried over sodium sulfate
(anhydrous). Solvent evaporation under reduced pressure and
purification by column chromatography over neutral alumina, using
ethyl acetate in petroleum ether as eluent, yielded 55 g (90%) of
the sub-title compound as an off-white solid.
(ii) 3-(4-Cyanophenyl)propionic acid ethyl ester
[0187] Pd/C (5 g, 10%) was added to a solution of
3-(4-cyanophenyl)acrylic acid ethyl ester (50 g, 0.25 mol; see step
(i) above) in dry ethyl acetate (500 mL) under a nitrogen
atmosphere, followed by triethylamine (50.3 g, 0.5 mol) and formic
acid (57.2 g, 1.24 mol). The mixture was refluxed overnight under a
nitrogen atmosphere. After the completion of the reaction
(monitored by TLC), the mixture was filtered and the filtrate then
washed with water, 5% NaHCO.sub.3 solution and brine, before being
dried over sodium sulfate. Solvent evaporation under reduced
pressure yielded 50 g (99%) of the sub-title compound as a pale
yellow oil.
(iii) 4-(3-Hydroxypropyl)benzonitrile
[0188] To a solution of LiBH.sub.4 (14 g, 0.65 mol) in dry ether
(400 mL) was added 3-(4-cyanophenyl)propionic acid ethyl ester (50
g, 0.249 mol; see step (ii) above), followed by methanol (27 mL)
dropwise. The reaction mixture was refluxed for 3 h. After
completion (monitored by TLC), the reaction was quenched by adding
cold, saturated ammonium chloride solution (100 mL), followed by
water (300 mL). The layers were then separated. The aqueous layer
was extracted with ether (2.times.100 mL) and the combined organic
layers were washed with brine. After drying over anhydrous sodium
sulfate, the organic layer was concentrated to give the crude
product. This crude product was purified by column chromatography
over silica gel, using ethyl acetate in petroleum ether as eluent.
This yielded 16.5 g (42%) of the sub-title compound as a pale
yellow liquid.
(iv) 4-(3-Bromopropyl)benzonitrile
[0189] To a solution of 4-(3-hydroxypropyl)benzonitrile (13 g,
0.081 mol; see step (iii) above) and triphenylphosphine (42.3 g,
0.16 mol) in DCM (150 mL) was added, dropwise at 0-5.degree. C., a
solution of CBr.sub.4 (53.5 g, 0.16 mol) in DCM (100 mL). The
resulting mixture was stirred at room temperature overnight. The
reaction mixture was concentrated and the product was purified by
column chromatography over silica gel, using petroleum ether in
ethyl acetate as eluent, to yield 12.5 g (69%) of the sub-title
compound as a yellow liquid.
(v) 4-[3-(2-Hydroxyethylamino)propyl]benzonitrile
[0190] To a solution 4-(3-bromopropyl)benzonitrile (8 g, 0.0357
mol; see step (iv) above) in dry acetonitrile (150 mL) were added
anhydrous K.sub.2CO.sub.3 (7.4 g, 0.0535 mol) and ethanolamine
(10.9 g, 0.179 mol). The resulting reaction mixture was then
stirred overnight at room temperature, after which it was filtered
and concentrated. The crude product thus obtained was purified by
column chromatography over silica gel, using methanol in chloroform
as eluent, to yield 4.2 g (57.5%) of the sub-title compound as a
pale yellow solid.
(vi) Methanesulfonic acid
2-{[3-(4-cyanophenyl)propyl]methanesulfonyl-amino}ethyl ester
[0191] To a solution of
4-[3-(2-hydroxyethylamino)propyl]benzonitrile (4 g, 0.0196 mol; see
step (v) above) in dry DCM (80 mL) were added, at 0-5.degree. C.,
triethylamine (5.9 g, 0.0588 mol) and mesyl chloride (5.6 g, 0.049
mol). The resulting mixture was then stirred at room temperature
for 30 min, after which the reaction was quenched by addition of
water (50 mL). The resulting aqueous layer was extracted with DCM
(2.times.50 mL) and the combined organic layers were washed with
brine. Solvent was removed under reduced pressure and the crude
product was recrystallised from methanol to yield 4.2 g (62%) of
the title compound as a white solid.
Preparation B
N-[3-(4-Cyanophenyl)propyl]-N-[2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)et-
hyl]methanesulfonamide, hydrochloride salt
(i)
7-(2-{[3-(4-Cyanophenyl)propyl]methanesulfonylamino}ethyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
[0192] A mixture of
9-oxa-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl
ester (2.35 g, 0.01 mol; see WO 01/28992), methanesulfonic acid
2-{[3-(4-cyanophenyl)propyl]methanesulfonylamino}ethyl ester (3.7
g, 0.01 mol; see Preparation A above) and anhydrous K.sub.2CO.sub.3
(2.1 g, 0.015 mol) in dry acetonitrile (70 mL) was stirred under
nitrogen atmosphere at 55-60.degree. C. for 3 days. After
filtration and concentration, the crude product was purified by
column chromatography (silica gel: 60-120 mesh, eluent: petroleum
ether-ethyl acetate, 50:50). Yield: 3.25 g (66%).
(ii)
N-[3-(4-Cyanophenyl)propyl]-N-[2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3--
yl)ethyl]methanesulfonamide hydrochloride salt
[0193]
7-(2-{[3-(4-cyanophenyl)propyl]methanesulfonylamino}ethyl)-9-oxa-3,-
7-diazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester (3.8
g, 0.0095 mol; see step (i) above) was added to a saturated
solution of HCl.sub.(g) in ethyl acetate (50 mL) and the resultant
mixture was then stirred overnight. On completion of the reaction
(as determined by TLC), ethyl acetate was decanted and the product
was dried under high vacuum to give the title compound. Yield: 1.5
g (54%).
Preparation C
N-(2-Bromoethyl)-N-[2-(4-cyanophenoxy)ethyl]methanesulfonamide
(i) 4-(2-Bromoethoxy)benzonitrile
[0194] Anhydrous potassium carbonate (233 g, 1.68 mol) was added to
a solution of 4-hydroxybezonitrile (100 g, 0.84 mol) in DMF (700
mL), and the resultant mixture was stirred for 1 h under a N.sub.2
atmosphere. 1,2-Dibromoethane (362 mL, 4.2 mol) was added slowly to
the reaction mixture, which was then stirred at 55-60.degree. C.
overnight. The reaction mixture was diluted with water and
extracted with ethyl acetate (3.times.750 mL). The combined organic
layer was washed with water and then concentrated. The crude
product was purified by column chromatography (silica gel: 60-120
mesh, eluent: petroleum ether-ethyl acetate, 90:10). Yield: 60 g
(32%).
(ii) 4-[2-(2-Hydroxyethylamino)ethoxy]benzonitrile
[0195] 4-(2-Bromoethoxy)benzonitrile (30 g, 0.133 mol; see step (i)
above) and ethanolamine (48 mL, 0.78 mol) were mixed and refluxed,
under a nitrogen atmosphere, at about 120.degree. C. for 3 h. The
reaction was quenched by addition of a sodium hydroxide solution to
the mixture. The sub-title compound was extracted using DCM
(2.times.250 .mu.L), which was dried over anhydrous sodium sulfate
and then concentrated. Yield: 13.1 g (48%).
(iii) Methanesulfonic acid
2-{[2-(4-cyanophenoxy)ethyl]methanesulfonyl-amino}ethyl ester
[0196] To a solution of
4-[2-(2-hydroxyethylamino)ethoxy]benzonitrile (14 g, 0.068 mol; see
step (ii) above) in dry DCM (200 mL) was added triethylamine (28.4
mL, 0.2 mol), followed by methanesulfonyl chloride (13 mL, 0.17
mol) at 0-5.degree. C. The reaction mixture was stirred at room
temperature for 1 h. After completion of the reaction (by TLC),
water (250 mL) was added and the organic layer was separated. The
aqueous layer was extracted with DCM (2.times.100 mL) and the
combined organic layers were washed with water. After
concentration, the crude product was further purified by column
chromatography (silica gel: 60-120 mesh, eluent:
chloroform-methanol, 98.5:1.5). Yield: 18.2 g (74%).
(iv)
N-(2-Bromoethyl)-N-[2-(4-cyanophenoxy)ethyl]methanesulfonamide
[0197] To a solution of methanesulfonic acid
2-{[2-(4-cyanophenoxy)ethyl]-methanesulfonylamino}ethyl ester (10
g, 0.028 mol; see step (iii) above) in dry acetone (100 mL), was
added lithium bromide (4.8 g, 0.055 mol). The reaction mixture was
added refluxed overnight under a nitrogen atmosphere, before being
filtered and concentrated to give the title compound. Yield: 10 g
(97%).
Preparation D
Toluene-4-sulfonic acid 2-{1-[2-(4-cyanophenoxy)ethyl]ureido}ethyl
ester
(i) N-[2-(4-Cyanophenoxy)ethyl]-N-(2-hydroxyethyl)urea
[0198] To a solution of
4-[2-(2-hydroxyethylamino)ethoxy]benzonitrile (5 g, 0.0242 mol; see
Preparation C(ii) above) in dioxane (65 mL) and water (65 mL) was
added, at rt, potassium cyanate (4.92 g, 0.0606 mol), followed by
acetic acid (4.36 g, 0.0726 mol). The reaction mixture was then
stirred at rt overnight, before being concentrated under reduced
pressure. The resulting residue was partitioned between water and
dichloromethane. The organic layer was separated, washed with water
and brine, dried over sodium sulfate and then concentrated. The
crude product was further purified by column chromatography. Yield:
3.5 g.
(ii) Toluene-4-sulfonic acid
2-{1-[2-(4-cyanophenoxy)ethyl]ureido}ethyl ester
[0199] To a solution of intermediate
1-[2-(4-cyanophenoxy)ethyl]-1-(2-hydroxyethyl)urea (4.7 g, 0.0188
mol; see step (i) above) in dry THF (150 mL) was added
n-butyllithium (18.89 mL, 1.1 M) at -78.degree. C. The reaction
mixture was stirred at -78.degree. C. for 1 h, after which a
solution of freshly crystallised p-toluenesulfonyl chloride (4.3 g,
0.023 mol) in THF (50 mL) was added dropwise. The reaction mixture
was then stirred at -78.degree. C. for a further 30 min, before
being warmed to -30.degree. C., and stirred for 2 h more. The
reaction mixture was quenched with water and extracted with ethyl
acetate. The organic layer was washed with brine, dried over
Na.sub.2SO.sub.4, concentrated and the residue was recrystallised
in ethyl acetate/hexane to yield the title compound as an off-white
solid. Yield: 3.5 g.
Preparation E
N-[2-(4-Cyanophenoxy)ethyl]-N-[2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)et-
hyl]urea
(i)
7-(2-{1-[2-(4-Cyanophenoxy)ethyl]ureido}ethyl)-9-oxa-3,7-diazabicyclo--
[3.3.1]nonane-3-carboxylic acid tert-butyl ester
[0200] A mixture of toluene-4-sulfonic acid
2-{1-[2-(4-cyanophenoxy)ethyl]-ureido}ethyl ester (15 g, 0.0372
mol, 1.0 eq.; see Preparation D above),
9-oxa-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl
ester (8.525 g, 0.0372 mol, 1.0 eq.; see WO 01/28992), fused
K.sub.2CO.sub.3 (7.7 g, 0.0558 mol, 1.5 eq.) and lithium bromide
(9.6 g, 0.1116 mol, 3.0 eq.) in dry acetonitrile (350 mL) was
heated to 40.degree. C. under N.sub.2 for 4 days. The reaction was
cooled to rt, filtered and the filtrate was concentrated under
reduced pressure. The resulting residue was purified by column
chromatography over silica gel, using 3% methanol and DCM as
eluent, to yield the sub-title compound as a white solid. Yield: 7
g, 40.9%.
(ii)
N-[2-(4-Cyanophenoxy)ethyl]-N-[2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3--
yl)ethyl]urea
[0201]
7-(2-{1-[2-(4-Cyanophenoxy)ethyl]ureido}ethyl)-9-oxa-3,7-diazabicyc-
lo-[3.3.1]nonane-3-carboxylic acid tert-butyl ester (6.44 g; see
step (i) above) was added to a solution of HCl-saturated, dry
dioxane (300 mL) at 0.degree. C. The reaction was then stirred at
rt for 1 hr. The resulting precipitate was filtered under N.sub.2,
washed with dry ether and then dried under vacuum to provide the
title compound. Yield: 6 g.
Preparation F
Toluene-4-sulfonic acid 2-{1-[3-(4-cyanophenyl)propyl]ureido}ethyl
ester
(i) 1-[3-(4-Cyanophenyl)propyl]-1-(2-hydroxyethyl)urea
[0202] 4-[3-(2-Hydroxyethylamino)propyl]benzonitrile (6.7 g, 0.0328
mol; see Preparation A(v) above) and urea (2 g, 0.0328 mol) were
mixed and heated at 130.degree. C. for 2 h. The reaction mixture
was cooled to room temperature and water was added. The resulting
solid was filtered and dried to give 5.9 g (72%) of the sub-title
compound as a white solid.
(ii) Toluene-4-sulfonic acid
2-{1-[3-(4-cyanophenyl)propyl]ureido}ethyl ester
[0203] 1-[3-(4-Cyanophenyl)propyl]-1-(2-hydroxyethyl)urea (5.9 g,
0.0238 mol; see step (i) above) was taken in dry pyridine (20 mL).
Freshly prepared p-toluenesulfonyl chloride (4.9 g, 0.02627 mol)
was then added portion-wise at 0.degree. C. The reaction mixture
was stirred at 0.degree. C. for 3 h, after which ethyl acetate was
added (to remove pyridine from product) and the resulting solid was
filtered. The product was then purified by column chromatography,
using methanol in dichloromethane as the eluent, followed by
crystallisation from isopropanol. This yielded 2.7 g (62%) of the
title compound as a colourless, crystalline solid.
[0204] .sup.1H NMR (300 MHz; CD.sub.3OD) .delta. 7.76-7.70 (m, 4H),
7.45 (d, 2H), 7.27 (d, 2H), 4.75 (t, 2H), 3.95 (t, 2H), 3.52 (t,
2H), 2.83 (t, 2H), 2.41 (s, 3H), 2.0 (m, 2H);
[0205] .sup.13C NMR (75.5 MHz, CD.sub.3OD) .delta. 163.46, 148.78,
144.13, 142.18, 133.91, 131.06, 130.34, 127.41, 120.34, 111.47,
70.52, 48.65, 46.13, 34.05, 29.20, 21.81.
Preparation G
1-[2-(4-Cyanophenoxy)ethyl]-3,3-dimethyl-1-(2-oxoethyl)urea
(i)
1-[2-(4-Cyanophenoxy)ethyl]-1-(2-hydroxyethyl)-3,3-dimethylurea
[0206] 4-{2-[(2-Hydroxyethyl)amino]ethoxy}benzonitrile (5 g, 0.0242
mol; see Preparation C, step (ii) above) was taken in dry
dichloromethane (50 mL) and cooled to 0.degree. C. Triethylamine (4
mL, 0.03 mol), followed by N,N-dimethylcarbamoyl chloride (3.9 g,
0.03 mol), was added, and the reaction mixture was stirred at room
temperature overnight. The reaction mixture was diluted with water
and extracted with dichloromethane. The organic layer was washed
with water and brine and dried over sodium sulfate. The solvent was
evaporated under reduced pressure. Purification by column
chromatography using dichloromethane in methanol yielded 6 g of the
sub-title compound as pale yellow liquid.
(ii)
1-[2-(4-Cyanophenoxy)ethyl]-3,3-dimethyl-1-(2-oxoethyl)urea
[0207] Oxalyl chloride (6.3 g, 0.0497 mol) was added dropwise to a
stirred solution of DMSO (7.6 g, 0.094 mol) and dichloromethane
(100 mL) at -78.degree. C. After stirring for 15 min at the same
temperature,
1-[2-(4-cyanophenoxy)ethyl]-1-(2-hydroxyethyl)-3,3-dimethylurea (6
g, 0.0325 mol; see step (i) above) in dichloromethane was added and
stirring continued for 3 h under a nitrogen atmosphere.
Triethylamine (16.4 mL, 0.1625 mol) was added dropwise and the
reaction mixture was then warmed slowly to -30.degree. C. The
reaction mixture was quenched with an aqueous solution of citric
acid, and the resulting mixture extracted with dichloromethane. The
organic layer was washed with water and brine and dried over sodium
sulfate. Solvent evaporation under reduced pressure yielded 4.5 g
of the crude title compound, which was used without further
purification.
Preparation H
1-[2-(4-Cyanophenoxy)ethyl]-3,3-dimethyl-1-[2-(9-oxa-3,7-diazabicyclo[3.3.-
1]non-3-yl)ethyl]urea
[0208]
7-(2-{1-[2-(4-Cyanophenoxy)ethyl]-3,3-dimethylureido}ethyl)-9-oxa-3-
,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
(6.5 g; see Example 5 below) was taken in HCl in dioxane (50 mL)
and stirred for 30 min. The reaction mixture was decanted and the
solid was taken in a biphasic mixture of dichloromethane and
aqueous NaHCO.sub.3. The organic layer was separated, washed with
water, dried over sodium sulfate and concentrated. Purification by
column chromatography yielded 1.3 g of the title compound as pale
yellow solid.
Preparation I
Toluene-4-sulfonic acid
2-{1-[2-(4-cyanophenoxy)ethyl]-3-methylureido}-ethyl ester
(i) 1-[2-(4-Cyanophenoxy)ethyl]-1-(2-hydroxyethyl)-3-methylurea
[0209] 4-[2-(2-Hydroxyethylamino)ethoxy]benzonitrile (1 g, 0.009
mol; see Preparation C, step (ii) above) and N,N'-dimethylurea
(0.43 g, 0.0049 mol) were heated with stirring at 130.degree. C.
for 4 h. The reaction was directly purified by column
chromatography to yield 0.7 g of the sub-title product as an off
white solid.
(ii) Toluene-4-sulfonic acid
2-{1-[2-(4-cyanophenoxy)ethyl]-3-methylureido}ethyl ester
[0210] To a well-stirred solution of
1-[2-(4-cyanophenoxy)ethyl]-1-(2-hydroxyethyl)-3-methylurea (6.6 g,
0.0257 mol; see step (i) above) in dry THF (70 mL) was added n-BuLi
(2.85 N, 1.766 g, 0.0276 mol) at -78.degree. C., dropwise under a
nitrogen atmosphere. After stirring at the same temperature for 45
min, p-toluenesulfonyl chloride (5.25 g, 0.0276 mol) in dry THF was
added (drop by drop) and the reaction mixture was then stirred at
-40.degree. C. for 2 h. The reaction was quenched with 50 mL water
and warmed to room temperature. The product was extracted with
ethyl acetate, washed with brine solution and dried over sodium
sulfate. Solvent evaporation under reduced pressure, followed by
column chromatography over silica gel (using 15-25% methanol in
chloroform) yielded 1.36 g of the title compound as a brown gummy
liquid.
Preparation J
1-[2-(4-Cyanophenoxy)ethyl]-3-methyl-1-[2-(9-oxa-3,7-diazabicyclo[3.3.1]-n-
on-3-yl)ethyl]urea, hydrogen chloride salt
[0211]
7-(2-{1-[2-(4-Cyanophenoxy)ethyl]-3-methylureido}ethyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester (920
mg; see Example 6 below) was dissolved in 10 mL of dry dioxane, to
which was added 10 mL of dioxane saturated with HCl. The reaction
mixture was stirred at room temperature for 1 h. The solid that
formed was filtered, washed with dry diethyl ether and then dried
under vacuum to yield 400 mg of the title compound as a yellow
solid.
Preparation K
1-[3-(4-Cyanophenyl)propyl]-3,3-dimethyl-1-(2-oxoethyl)urea
(i) 4-[3-(2-Hydroxyethylamino)propyl]benzonitrile
[0212] 4-(3-Bromopropyl)benzonitrile (20 g, 0.089 mol) in
acetonitrile was added to a vigorously stirred mixture of
ethanolamine (27.2 g, 0.447 mol) and potassium carbonate (18.5 g,
0.133 mol) in 300 mL of dry acetonitrile. Stirring was then
continued at room temperature overnight under a nitrogen
atmosphere. The reaction mixture was filtered and concentrated
under reduced pressure. The crude product thereby obtained was
purified by column chromatography (using methanol in chloroform) to
yield 15 g of the sub-title compound.
(ii)
1-[3-(4-Cyanophenyl)propyl]-1-(2-hydroxyethyl)-3,3-dimethylurea
[0213] N,N-Dimethylcarbamoyl chloride (3.9 g, 0.0368 mol) was added
to a mixture of 4-[3-(2-hydroxyethylamino)propyl]benzonitrile (5 g,
0.025 mol; see step (i) above) and triethylamine (3.7 g, 0.368 mol)
in dichloromethane (100 mL) at 0.degree. C. Stirring was then
continued at room temperature overnight. The reaction mixture was
diluted with water and extracted with dichloromethane. The organic
layer was washed with water and brine and dried over sodium
sulfate. Solvent evaporation under reduced pressure, followed by
purification by column chromatography (using 4% methanol in
dichloromethane) yielded 7 g of the sub-title compound as a pale
yellow, gummy liquid.
(iii)
1-[3-(4-Cyanophenyl)propyl]-3,3-dimethyl-1-(2-oxoethyl)urea
[0214] Oxalyl chloride (4.84 g, 0.038 mol) was added dropwise to a
stirred solution of DMSO (5.9 g, 0.0763 mol) and dichloromethane
(100 mL) at -78.degree. C. After 15 min at the same temperature,
1-[3-(4-cyanophenyl)propyl]-1-(2-hydroxyethyl)-3,3-dimethylurea (7
g, 0.0254 mol) in dichloromethane was added and stirring continued
for 3 h under a nitrogen atmosphere. Triethylamine (12.8 g, 0.127
mol) was added (dropwise), and the reaction mixture was then warmed
slowly to -30.degree. C. The reaction mixture was quenched with 10%
citric acid (aq.) and extracted with dichloromethane. The organic
layer was washed with water and brine, dried over sodium sulfate
and concentrated to yield 6.5 g of the crude title compound, which
was used without further purification.
Preparation L
1-[3-(4-Cyanophenyl)propyl]-3,3-dimethyl-1-[2-(9-oxa-3,7-diazabicyclo[3.3.-
1]non-3-yl)ethyl]urea, hydrogen chloride salt
[0215]
7-(2-{1-[3-(4-Cyanophenyl)propyl]-3,3-dimethylureido}ethyl)-9-oxa-3-
,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
(7.5 g; see Example 7 below) was taken in dioxane (20 mL, saturated
with HCl gas) and stirred for 2 h. The organic layer was decanted
and the residue was washed with dry diethyl ether and dried under
vacuum to yield 3 g the title compound as a pale yellow solid.
Preparation M
N-{2-[7-(4-Cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-metha-
nesulfonamide
(i)
7-(4-Cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic
acid tert-butyl ester
[0216] 4-Cyanobenzyl bromide (2 g, 0.01 mol),
9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl
ester (2.33 g, 0.01 mol; see WO 01/28992) and potassium carbonate
(3.52 g, 0.026 mol) were taken in dry acetonitrile (25 mL) and
stirred at 60.degree. C. overnight under a nitrogen atmosphere. The
reaction mixture was cooled to rt, filtered and the filtrate
concentrated under reduced pressure. The residue obtained thereby
was purified by column chromatography (using 5% ethyl acetate in
petroleum ether) to yield 2.6 g of the sub-title compound as a
white solid.
(ii) 4-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-ylmethyl)benzonitrile,
hydrogen chloride salt
[0217]
7-(4-Cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic
acid tert-butyl ester (2.2 g) was taken in dioxane (25 mL,
saturated with HCl gas) and the reaction mixture stirred at room
temperature for 3 h. The dioxane was decanted off the solid
product, which was then washed with diethyl ether and dried under
vacuum to yield 1.82 g of the sub-title compound as a white
solid.
(iii) N-(2-Bromoethyl)methanesulfonamide
[0218] A suspension of 2-bromoethylamine hydrobromide salt (15 g,
0.0724 mol) in dichloromethane (220 mL) was treated with
triethylamine (18.31 g, 0.181 mol) for 30 min. Into the resulting
mixture was added, dropwise at 0.degree. C., methanesulfonyl
chloride (9.11 g, 0.0796 mol). The reaction mixture was then
stirred at room temperature for 3 h before being quenched with
water. The organic layer was washed with water and then brine
before being dried over sodium sulfate. Solvent evaporation under
reduced pressure followed by column chromatography over silica gel
(using 2% ethyl acetate in petroleum ether as eluent) gave 4.5 g of
the sub-title compound as a pale yellow oil.
(iv)
N-{2-[7-(4-Cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]-ethyl}-
methanesulfonamide
[0219] 4-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-ylmethyl)benzonitrile,
hydrogen chloride salt (1 g, 3.1 mmol; see step (ii) above),
N-(2-bromoethyl)methanesulfonamide (0.75 g, 3.72 mmol; see step
(iii) above) and potassium carbonate (1.07 g, 7.75 mmol) were taken
in dry acetonitrile (20 mL) and stirred for 15 min at rt under a
nitrogen atmosphere. The reaction mixture was concentrated under
reduced pressure and the residue obtained thereby was partitioned
between water and dichloromethane. The organic layer washed with
water followed by brine and was then dried over sodium sulfate.
Evaporation of the solvent followed by vacuum drying of the residue
gave 0.9 g of the title compound as a brown solid.
Preparation N
N-Benzyl-N-[2-(9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl)-ethyl]-methanesulfo-
namide hydrochloride
(i) N-benzyl ethanolamine
[0220] A mixture of benzyl bromide (15 g, 0.0872 mol) and ethanol
amine (26.5 g, 0.436 mol) was stirred at 120.degree. C. for 3 h.
The reaction mixture was diluted with brine and extracted with
dichloromethane. The organic layer was washed with water and brine
and dried over sodium sulfate. Solvent evaporated under reduced
pressure and the residue was purified by column chromatography over
silica gel using 4% methanol in dichloromethane as eluent to give
N-benzyl ethanolamine (12 g) as a liquid.
(ii) Methanesulfonic acid 2-(benzyl-methanesulfonyl-amino)-ethyl
ester
[0221] Methanesulfonyl chloride (18.9 g, 0.1655 mol) was added
dropwise at 0.degree. C. to a solution of N-benzyl ethanolamine (10
g, 0.0662 mol, from step (i) above) and triethylamine (27.6 ml,
0.1987 mol) in dichloromethane (100 ml). The reaction mixture was
stirred at RT for 3 h under nitrogen atmosphere and partitioned
between water and dichloromethane. The organic layer was separated,
washed with water and brine and dried over sodium sulfate. The
solvent was evaporated under reduced pressure and the residue was
purified by column chromatography over silica gel using 3% methanol
in dichloromethane, as eluent to give the sub-title compound (12 g)
as a solid.
(iii)
7-[2-(Benzyl-methanesulfonyl-amino)-ethyl]-9-oxa-3,7-diazabicyclo[3.-
3.1]nonane-3-carboxylic acid tert-butyl ester
[0222] A suspension of methanesulfonic acid
2-(benzyl-methanesulfonyl-amino)-ethyl ester (4 g, 0.0130 mol; from
step (ii) above), 9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic
acid tert-butyl ester (3 g, 0.013 mol; see WO 01/28992)), dry
K.sub.2CO.sub.3 (3.6 g, 0.026 mol) and lithium bromide (2.2 g,
0.026 mol) in dry acetonitrile (50 ml) was stirred at 60.degree. C.
overnight under N.sub.2. The reaction mixture was filtered and
filtrate was concentrated under reduced pressure. The residue was
purified by column chromatography over silica gel using 4% methanol
in dichloromethane as eluent to yield (5 g) of the sub-title
compound as a solid.
(iv)
N-Benzyl-N-[2-(9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl)-ethyl]-methane-
sulfonamide hydrochloride
[0223]
7-[2-(Benzyl-methanesulfonyl-amino)-ethyl]-9-oxa-3,7-diazabicyclo[3-
.3.1]nonane-3-carboxylic acid tert-butyl ester (5 g, 0.011 mol,
from step (iii) above) was taken in 20 ml of dioxane (saturated
with HCl gas) and stirred for 30 min at room temperature. The
precipitated solid was filtered, washed with dry ether and dried
under vacuum to yield (3 g) of the title compound as an off white
solid.
Preparation O
Methanesulfonic acid 2-(methanesulfonyl-phenethyl-amino)-ethyl
ester
(i) 2-Phenethylamino-ethanol
[0224] A mixture of ethanolamine (10 g, 0.162 mol) and
1-phenylethyl bromide (5 g, 0.027 mol) was stirred at 120.degree.
C. for 3 h. The reaction mixture was partitioned between water and
dichloromethane. Organic layer was washed with water and brine,
dried over sodium sulfate and concentrated. The residue was
purified by column chromatography over silica gel using 3% methanol
in dichloromethane to afford (2.5 g) of desired product as a
solid.
(ii) Methanesulfonic acid 2-(methanesulfonyl-phenethyl-amino)-ethyl
ester
[0225] Methanesulfonyl chloride (4.3 g, 0.037 mol) was added
dropwise at 0.degree. C. to a well stirred solution of
2-phenethylamino-ethanol (2.5 g, 0.015 mol, from step (i) above)
and triethylamine (4.6 g, 0.045 mol) in dry dichloromethane (50
ml). The reaction mixture was stirred at room temperature for 3 h
and quenched with water. The reaction mixture was extracted with
dichloromethane. The organic layer was washed with water and brine,
dried over sodium sulfate and concentrated. The residue was
purified by column chromatography over silica gel using 3% methanol
in dichloromethane as eluent to yield (3 g) of compound as a
solid.
Preparation P
Methanesulfonic acid
2-[methanesulfonyl-(2-phenoxy-ethyl)-amino]-ethyl ester
(i) (2-Bromo-ethoxy)-benzene
[0226] A suspension of phenol (5 g, 0.053 mol), 1,2-dibromethane
(60 g, 0.319 mol) and K.sub.2CO.sub.3 (22 g, 0.16 mol) in dry
acetonitrile (100 ml) was stirred at 60.degree. C. overnight under
nitrogen atmosphere. The reaction mixture was filtered and the
solvent concentrated under reduced pressure. The residue was
purified by column chromatography over silica gel using 10% ethyl
acetate in petroleum ether as eluent to yield (10 g) of the
sub-title compound as a solid.
(ii) 2-(2-Phenoxy-ethylamino)-ethanol
[0227] A mixture of ethanolamine (18.2 g, 0.298 mol) and
(2-Bromoethoxy)-benzene (10 g, 0.0497 mol, from step (i) above) was
stirred at 120.degree. C. for 3 h. The reaction mixture was
partitioned between water and dichloromethane. Organic layer was
washed with water and brine, dried over sodium sulfate and
concentrated. Residue was purified by column chromatography over
silica gel using 4% methanol in dichloromethane to afford (3.8 g)
of the sub-title compound as a solid.
(iii) Methanesulfonic acid
2-[methanesulfonyl-(2-phenoxy-ethyl)-amino]-ethyl ester
[0228] Methanesulfonyl chloride (5.5 g, 0.058 mol) was added
dropwise by at 0.degree. C. to a well stirred solution of
2-(2-phenoxy-ethylamino)-ethanol (3.5 g, 0.0193 mol, from step (ii)
above) and triethylamine (5.85 g, 0.058 mol) in dry dichloromethane
(50 ml). The reaction mixture was stirred at room temperature for 3
h and quenched with water. The compound was extracted with
dichloromethane. The organic layer was washed with water and brine,
dried over sodium sulfate and concentrated. The residue was
purified by column chromatography over silica gel using 2% methanol
in dichloromethane as eluent to yield (4 g) of the title compound
as a yellow solid.
Preparation Q
Trifluoro-methanesulfonic acid
2-(benzyl-trifluoromethanesulfonyl-amino)-ethyl ester
[0229] (i): Triflic anhydride (11.18 g, 6.5 ml, 39 mmol) dissolved
in 90 ml of DCM was added drop by drop to a well stirred solution
of N-benzyl ethanol amine (2 g, 13.2 mmol) and diisopropylethyl
amine (5.1 g, 6.9 ml, 39.7 mmol) in dichloromethane (160 ml) at
0.degree. C. and stirred at room temperature for 1 h under nitrogen
atmosphere. The reaction mixture was quenched with water and
extracted with dichloromethane. Organic layer was washed with water
and dried under sodium sulfate. Solvent evaporation under reduced
pressure afforded 500 mg of the title compound as a an oil
Preparation R
Toluene-4-sulfonic acid 2-(1-benzyl-3-methyl-ureido)-ethyl
ester
(i) 1-Benzyl-1-(2-hydroxy-ethyl)-3-methyl-urea
[0230] A mixture of N-benzyl ethanolamine (3 g, 0.0198 mol) and
N,N'-dimethyl urea was stirred at 130.degree. C. overnight. The
reaction mixture was cooled to RT and the crude product was
purified by column chromatography over silica gel using 3% methanol
in dichloromethane as eluent to yield 3.5 g of the sub-title
compound as a liquid.
(ii) Toluene-4-sulfonic acid 2-(1-benzyl-3-methyl-ureido)-ethyl
ester
[0231] nBuLi (2.8 N, 1.01 g, 0.0157 mol) was added at -78.degree.
C. to a solution of 1-benzyl-1-(2-hydroxy-ethyl)-3-methyl-urea (3
g, 0.0143 mol, from (i) above) in 30 ml of dry THF and stirred at
same temperature for 30 min under nitrogen atmosphere.
P-Toluenesulfonyl chloride (3 g, 0.0157 mol) in 20 ml of dry THF
was added dropwise at -78.degree. C. and stirred for 3 h under
nitrogen atmosphere. The reaction was quenched with methanol and
solvent evaporated under reduced pressure. The crude was purified
by column chromatography over silica gel using 12% methanol in
dichloromethane as eluent to yield 2.5 g of the title compound as a
solid.
Preparation S
Ethanesulfonic acid 2-(benzyl-ethanesulfonyl-amino)-ethyl ester
[0232] Ethanesulfonyl chloride (2.1 g, 16.6 mmol) was added
dropwise at 0.degree. C. to a well-stirred solution of N-benzyl
ethanolamine (1 g, 6.6 mmol) and triethylamine (2.8 ml. 19 mmol) in
dry dichloromethane (10 ml). The reaction mixture was stirred at
room temperature for 1 h and quenched with water. The compound was
extracted with dichloromethane, the organic layer was washed with
water, brine and dried over sodium sulfate. Solvent evaporation
under reduced pressure, followed by column chromatography over
silica gel using 2% methanol in chloroform as eluent afforded (0.8
g) of the title compound as a liquid.
EXAMPLES
Example 1
N-[2-(7-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[2-(4-cyanop-
henoxy)ethyl]urea
[0233] 3-Benzyl-9-oxa-3,7-diaza-bicyclo[3.3.1]nonane (0.18 g, 0.82
mmol; see WO 01/28992) and toluene-4-sulfonic acid
2-{1-[2-(4-cyanophenoxy)ethyl]-ureido}ethyl ester (0.50 g, 1.24
mmol; see Preparation D above) were mixed in dry acetonitrile (15
mL) and stirred at 60.degree. C. overnight. DCM (10 mL) was added,
together with 0.5 g of PS--NCO (polymer-supported isocyanate). The
mixture was stirred for 2 h, then filtered and evaporated. The
crude product was put on a SCX-II (cat ion exchanger)-plug, which
plug was then eluted with DCM:MeOH(NH.sub.3-saturated), 80:20. The
product was further purified on a Horizon prep. column (40 g, A:
DCM (1% MeOH), B: DCM/MeOH(NH.sub.3-sat.), 80:20. Gradient 0-30% B
over 1080 mL). The product was then further purified by prep. HPLC
and finally extracted with DCM/Na.sub.2CO.sub.3 (aq.) to give 193
mg (51.9%) of the title compound.
[0234] .sup.13C NMR (100.6 MHz, CDCl.sub.3) .delta. 162.2, 161.5,
136.2, 134.3, 129.9, 128.6, 127.7, 119.3, 115.3, 104.4, 68.6, 67.9,
64.2, 61.4, 57.3, 56.1, 49.2, 48.7
Example 2
N-[2-(7-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[2-(4-cyanop-
henoxy)ethyl]methanesulfonamide, tartaric acid salt
[0235] Methanesulfonic acid
2-{[2-(4-cyanophenoxy)ethyl]methanesulfonylamino}ethyl ester (0.60
g, 1.65 mmol; see Preparation C(iii) above) and
3-benzyl-9-oxa-3,7-diaza-bicyclo[3.3.1]nonane (0.36 g, 1.65 mmol;
see WO 01/28992) were mixed in acetonitrile (12 mL). The resulting
solution was divided into 3 equal parts, which were put in
microwave vessels. K.sub.2CO.sub.3 (0.11 g, 0.46 mmol) was added to
each vessel and the reaction was run in the microwave reactor for
10 minutes at 160.degree. C. The reaction mixtures were filtered,
combined and then put on a 5 g SCX-plug. The plug was washed with
DCM, acetonitrile and DCM:MeOH (80:20) until all (relatively)
apolar material had been eluted. The product was then eluted with
DCM:MeOH(NH.sub.3-satd.) 80:20. Analysis by .sup.1H NMR showed
residual oxabispidine starting material, and so the product was
dissolved in DCM (30 mL) and 300 mg of polymer-supported isocyanate
was added. The resulting mixture was then stirred overnight.
Filtration and evaporation gave 450 mg of the pure, free base
product. This product was then dissolved in ethanol, to which was
added 1 equivalent (148.6 mg) of tartaric acid. The resulting
mixture was evaporated and dissolved in water. Freeze-drying
overnight then gave 623 mg (59%) of the title compound as a
colourless powder.
[0236] .sup.13C NMR (free base, 100.6 MHz, CDCl.sub.3) .delta.
161.7, 137.7, 134.3, 129.3, 128.5, 127.3, 119.2, 115.3, 104.8,
68.6, 67.6, 63.8, 59.0, 56.6, 56.4, 47.0, 44.9, 39.3
Example 3
N-[2-(4-Cyanophenoxy)ethyl]-N-{2-[7-(4-fluorobenzyl)-9-oxa-3,7-diazabicycl-
o[3.3.1]non-3-yl]ethyl}methanesulfonamide
(i)
7-(2-{[2-(4-Cyanophenoxy)ethyl]methanesulfonylamino}ethyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
[0237] To a suspension of
N-(2-bromoethyl)-N-[2-(4-cyanophenoxy)ethyl]methane-sulfonamide (6
g, 0.019 mol; see Preparation C above) and anhydrous potassium
carbonate (3.6 g, 0.026 mol) in dry acetonitrile (100 mL) was added
9-oxa-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl
ester (4.35 g, 0.019 mol; see WO 01/28992), and the resultant
mixture was then stirred at 50-55.degree. C. overnight. After
completion of the reaction (as determined by TLC), the mixture was
filtered and concentrated. The crude product was further purified
by column chromatography (silica gel: 60-120 mesh, eluent:
chloroform-methanol, 99:1). Yield: 4.2 g (46%).
(ii) N-[2-(4-Cyanophenoxy)ethyl]-N-[2-(9-oxa-3,7-diazabicyclo
F3.3.1 non-3-yl)ethyl]methanesulfonamide
[0238] To a saturated solution of HCl.sub.(g) in dioxane (100 mL)
was added
7-(2-{[2-(4-cyanophenoxy)ethyl]methanesulfonylamino}ethyl)-9-oxa-3,-
7-diazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester (3.5
g, 0.0070 mol; see step (i) above), after which the reaction was
stirred for 1 h. On completion of the reaction (as determined by
TLC), dioxane was decanted and product (semi-solid) dissolved in
methanol (25 mL). After concentrating the methanol, dry ether (50
mL) was added and the solvent was again concentrated. This was
repeated twice and finally the product was dried under high vacuum.
Yield: 3.0 g (99%).
(iii)
N-[2-(4-Cyanophenoxy)ethyl]-N-{2-[7-(4-fluorobenzyl)-9-oxa-3,7-diaza-
bicyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide
[0239]
N-[2-(4-Cyanophenoxy)ethyl]-N-[2-(9-oxa-3,7-diazabicyclo[3.3.1]non--
3-yl)ethyl]methanesulfonamide (0.079 g, 0.2 mmol; see step (ii)
above) and 1-bromomethyl-4-fluorobenzene (0.040 g, 0.21 mmol) and
K.sub.2CO.sub.3 (0.041 g, 0.3 mmol) were was mixed in a microwave
vessel and then heated in the microwave reactor for 15 min at
160.degree. C. The mixture was filtered and put on a SCX-II plug.
The plug was washed with DCM, acetonitrile, DCM/MeOH (80:20), after
which the product was eluted with DCM:MeOH(NH.sub.3-satd.), 80:20.
The product was purified on a 9 g Horizon prep. chromatography
column (A:DCM(1% MeOH), B:DCM/MeOH(NH.sub.3-satd.), 80:20. Gradient
0-25% B, 270 mL (9 mL fractions)), which gave 63 mg (62.7%) of the
title compound.
[0240] .sup.13C NMR (125.7 MHz, CDCl.sub.3) .delta. 160.5, 159.1,
158.6, 131.8, 130.9, 128.1, 128.0, 116.6, 112.8, 112.7, 112.6,
102.3, 65.9, 65.0, 60.3, 56.3, 54.0, 53.7, 44.4, 42.6, 36.6
Example 4
N-[2-(4-Cyanophenoxy)ethyl]-N-{2-[7-(pyridin-3-ylmethyl)-9-oxa-3,7-diazabi-
cyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide
[0241]
N-[2-(4-Cyanophenoxy)ethyl]-N-[2-(9-oxa-3,7-diazabicyclo[3.3.1]non--
3-yl)ethyl]methanesulfonamide (79 mg, 0.2 mmol; see Example 3(ii)
above) and pyridine-3-carbaldehyde (36 mg, 0.34 mmol) were
dissolved in DCM (4 mL) and shaken for 1.5 h. Sodium
triacetoxyborohydride (144 mg, 0.68 mmol) was added and the mixture
was shaken overnight. The reaction was quenched with 1 M
K.sub.2CO.sub.3 (2 mL) and was then phase-separated. The aqueous
layer was washed with DCM (3.times.3 mL) and the organic layers
were combined and evaporated. The residue was purified by
chromatography on silica, which gave 66 mg (68%) of the title
compound.
[0242] .sup.13C NMR (125.7 MHz, CDCl.sub.3) .delta. 161.7, 150.6,
148.7, 136.7, 134.4, 133.4, 123.5, 119.2, 115.35, 104.8, 68.5,
67.6, 60.9, 58.8, 58.5, 56.9, 56.6, 56.3, 47.1, 45.4, 39.1
Example 5
7-(2-{1-[2-(4-Cyanophenoxy)ethyl]-3,3-dimethylureido}ethyl)-9-oxa-3,7-diaz-
abicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
[0243] 1-[2-(4-Cyanophenoxy)ethyl]-3,3-dimethyl-1-(2-oxoethyl)urea
(4.5 g; see Preparation G above) was taken in dichloromethane (100
mL). 9-Oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid
tert-butyl ester (2.9 g, 0.013 mol; see WO 01/28992), followed by
glacial acetic acid (1.47 g, 0.0245 mol), was added, and reaction
mixture was stirred for 1 h. NaBH.sub.3CN (1.54 g, 0.024 mol) was
added at 0.degree. C., and stirring was continued overnight at room
temperature. The reaction mixture was diluted with water and
extracted with dichloromethane. The organic layer was washed with
water and brine and then dried over sodium sulfate. Solvent
evaporation, followed by purification by column chromatography,
yielded the title compound (6.5 g).
[0244] .sup.1H NMR (CDCl.sub.3, 300 MHz), .delta. 7.59 (d, 2H),
6.95 (d, 2H), 4.14-4.08 (m, 4H), 3.82-3.77 (m, 2H), 3.58-3.49 (3H,
m), 3.30-3.27 (m, 4H), 2.92-2.80 (m, 7H), 2.6-2.3 (m, 4H), 1.45 (s,
9H)
Example 6
7-(2-{1-[2-(4-Cyanophenoxy)ethyl]-3-methylureido}ethyl)-9-oxa-3,7-diazabic-
yclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
[0245] A mixture of toluene-4-sulfonic acid
2-{1-[2-(4-cyanophenoxy)ethyl]-3-methylureido}ethyl ester (1.35 g,
3.233 mmol; see Preparation I above),
9-oxa-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl
ester (1.48 g, 6.466 mmol; see WO 01/28992) and potassium carbonate
(1.34 g, 9.7 mmol) in dry acetonitrile (15 mL) was stirred at
45.degree. C. for 24 h. The reaction mixture was diluted with 20 nm
water and extracted with ethyl acetate. The organic layer was
washed with water, brine and dried over sodium sulfate. Solvent
evaporation under reduced pressure followed by column
chromatography over silica gel (using 2-2.5% methanol in
dichloromethane) and further purification by preparative HPLC
yielded 920 mg of the title compound as a white solid.
[0246] MS: 474 (M.sup.++H): calculated for
C.sub.24H.sub.35N.sub.5O.sub.5 (M.sup.++H) 474.
Example 7
7-(2-{1-[3-(4-Cyanophenyl)propyl]-3,3-dimethylureido}ethyl)-9-oxa-3,7-diaz-
abicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester
[0247] 1-[3-(4-Cyanophenyl)propyl]-3,3-dimethyl-1-(2-oxoethyl)urea
(6.5 g; see Preparation K above) was taken in dichloromethane (100
mL), to which was added
9-oxa-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl
ester (4.36 g, 0.019 mol; see WO 01/28992), followed by glacial
acetic acid (2.14 g, 0.0357 mol). The reaction mixture was stirred
for 1 h before NaBH.sub.3CN (2.24 g, 0.0357 mol) was added at
0.degree. C. Stirring was continued overnight at room temperature.
The reaction mixture was quenched with water and extracted with
dichloromethane. The organic layer was washed with water and brine
and dried over sodium sulfate. Solvent evaporation, followed by
purification by column chromatography over silica gel (using 2%
methanol in dichloromethane) yielded 7.5 g of the title compound as
a yellow, gummy liquid.
[0248] .sup.1H NMR (CDCl.sub.3, 300 MHz); .delta. 7.57 (d, 2H),
7.28 (d, 2H), 4.09-3.9 (m, 2H), 3.80-3.74 (m, 2H), 3.23-3.1 (m,
6H), 2.88-2.78 (m, 4H), 2.75 (s, 6H), 2.63 (t, 2H), 2.52 (t, 2H),
2.3-2.1 (m, 2H), 1.83 (t, 2H), 1.44 S, 9H)
Example 8
N-Benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]-et-
hyl}methanesulfonamide
[0249] To a suspension of NaH (60% in oil, 0.039 g, 1.64 mmol) in
dry DMF (10 mL) was added
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]-non-3-yl]ethyl}meth-
anesulfonamide (0.3 g, 0.82 mmol; see Preparation M above) at
0.degree. C. The reaction mixture was stirred for 1 h at room
temperature. Benzyl bromide (0.155 g, 0.9 mmol) was added at
0.degree. C. and the reaction mixture stirred at rt for 2 h. The
reaction quenched with water, extracted with dichloromethane,
washed with water, brine and then dried over sodium sulfate.
Solvent evaporation under reduced pressure, followed by column
chromatography of the residue over silica gel (using 5% methanol in
chloroform as eluent) gave 160 mg of the title compound as a pale
yellow solid.
[0250] .sup.13C NMR (75 MHz, CDCl.sub.3): .delta. 143.76, 136.07,
132.059, 129.30, 128.74, 128.14, 128.04, 118.83, 110.74, 68.17,
62.60, 57.70, 56.24, 55.94, 53.32, 51.38, 43.89, 39.18.
Example 9
N-(2-{7-[3-(4-Cyano-phenoxy)-propyl]-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-y-
l}-ethyl)-N-(2-phenoxy-ethyl)methanesulfonamide
[0251] (i) A suspension of
4-[3-(9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl)-propoxy]-benzonitrile
(1.5 g, 5.5 mmol, see WO 01/28992), methanesulfonic acid
2-[methanesulfonyl-(2-phenoxy-ethyl)-amino]-ethyl ester (1.51 g,
4.5 mmol, preparation P above) and dry K.sub.2CO.sub.3 (1.69 g,
12.3 mmol) in dry acetonitrile (100 ml) was stirred at 60.degree.
C. overnight under nitrogen atmosphere. The reaction mixture was
filtered and solvent concentrated under reduced pressure. The
residue was purified by column chromatography over silica gel using
3% methanol in dichloromethane as eluent to give the title compound
(1.4 g) as a liquid.
[0252] .sup.1H NMR (400 MHz, CD.sub.3Cl.sub.3) .delta. 7.57 (2H,
d), 7.30 (2H, d), 7.03-6.89 (5H, m), 4.22-4.12 (8H, m), 4.03-4.00
(3H, bt), 3.79-3.71 (4H, m), 3.37 (2H, m), 3.12 (2H, m), 3.00 (3H,
s) 2.85 (2H, m), 2.83-2.76 (2H, m), 2.50 (2H, bs)
Example 10
N-Benzyl-N-{2-[7-(4-cyano-benzyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl]--
ethyl}-benzenesulfonamide
(i) Benzenesulfonic acid 2-(benzenesulfonyl-benzyl-amino)-ethyl
ester
[0253] Benzenesulfonyl chloride (2.2 ml, 0.0175 mol) was added
dropwise at 0.degree. C. to a well-stirred solution of N-benzyl
ethanolamine (1 g, 0.7 mmol) and triethylamine (2.4 ml. 0.0175 mol)
in dry dichloromethane (10 ml). The reaction mixture was stirred at
room temperature for 1 h and quenched with water. The compound was
extracted with dichloromethane, organic layer was washed with
water, brine and dried over sodium sulfate. Solvent evaporation
under reduced pressure afforded 0.6 g of the desired product as a
solid. This was directly taken for next step without further
purification.
(ii)
N-Benzyl-N-{2-[7-(4-cyano-benzyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-
-yl]-ethyl}-benzenesulfonamide
[0254] A suspension of benzenesulfonic acid
2-(benzenesulfonyl-benzyl-amino)-ethyl ester (0.33 g, 1.04 mmol,
from step (i) above),
4-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-ylmethyl)benzonitrile,
hydrogen chloride salt (0.5 g, 1.16 mmol, from prep M (ii) above)
and potassium carbonate (0.64 g, 4.64 mmol) in dry acetonitrile (10
ml) was stirred at 60.degree. C. overnight under nitrogen
atmosphere. The reaction mixture was filtered and the filtrate was
concentrated under reduced pressure. The residue was purified by
column chromatography over silica gel using 10% methanol in
dichloromethane as eluent to yield 80 mg of the title compound as a
liquid.
[0255] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.67-7.63 (1H, m),
7.58-7.50 (6H, m), 7.30-7.27 (5H, m), 4.45 (2H, s), 3.85 (2H, bt),
3.72-3.64 (2H, bm), 3.37 (2H, m), 3.0-2.89 (4H, bm), 2.75-2.16 (6H,
bm)
Example 11
N-{2-[7-(2-Cyano-benzyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl]-ethyl}-N--
[2-(4-cyano-phenoxy)-ethyl]-methanesulfonamide
[0256] To
N-[2-(4-cyano-phenoxy)-ethyl]-N-[2-(9-oxa-3,7-diaza-bicyclo[3.3.-
1]-non-3-yl)-ethyl]-methanesulfonamide (0.079 g, 0.20 mmol),
2-bromo-methyl-benzonitrile (0.041 g, 0.21 mmol) and anhydrous
potassium carbonate (0.042 g, 0.30 mmol) was added dry acetonitrile
(4 mL). The mixture was heated by microwave irradiation (15
minutes, 160.degree. C.) and was then filtered. The filtrate was
loaded onto a cation exchange column (SCX-2, Isolute.TM., 2 g). The
column was washed with dichloromethane, acetonitrile and
dichloromethane/methanol 80:20 before eluting the crude product
with 20% methanol saturated with ammonia in dichloromethane. The
filtrate was concentrated in vacuo and the crude product was
purified by chromatography on silica gel using methanol saturated
with ammonia in dichloromethane as eluent, which afforded 57 mg
(55.9%) of the title compound.
[0257] .sup.13C NMR (125.7 MHz, CDCl.sub.3) .delta. 159.06, 139.57,
131.78, 130.64, 130.24, 127.71, 125.27, 116.56, 115.58, 112.75,
110.56, 102.33, 65.84, 64.92, 58.67, 55.85, 53.80, 53.58, 44.66,
43.17, 36.36
Example 12
N-(4-Cyano-benzyl)-N-{2-[7-(4-cyano-benzyl)-9-oxa-3,7-diazabicyclo[3.3.1]n-
on-3-yl]-ethyl}-methanesulfonamide
[0258] To a suspension of sodium hydride (0.013 g of a 60%
suspension in mineral oil, washed with pentane) in anhydrous
N,N-dimethylformamide (4 mL) was added
N-{2-[7-(4-Cyano-benzyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl]-ethyl}-m-
ethanesulfonamide (0.109 g, 0.30 mmol) at 0.degree. C. The mixture
was stirred for 2 hours while the temperature was allowed to warm
to room temperature. At 0.degree. C., 4-bromomethyl-benzonitrile
(0.065 g, 0.33 mmol) was added. The mixture was stirred for 2 hours
at room temperature, whereupon water (5 mL) was added. The aqueous
layer was extracted with dichloromethane (3.times.5 mL) and the
combined organic layers were dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude product was purified by
chromatography on silica gel using methanol saturated with ammonia
dichloromethane as eluent, which afforded 79 mg (54.9%) of the
title compound.
[0259] .sup.13C NMR (125.7 MHz, CDCl.sub.3) .delta. 143.69, 142.72,
132.69, 132.46, 129.68, 128.63, 119.13, 118.74, 112.01, 111.11,
68.40, 63.27, 57.99, 56.38, 51.57, 44.95, 39.06
Example 13
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]eth-
yl}-N',N'-dimethylurea
(i) 1-Benzyl-1-(2-hydroxy-ethyl)-3,3-dimethyl-urea
[0260] N,N-dimethyl carbamoyl chloride (2.55 g, 0.0238 mol) was
added drop by drop at 0.degree. C. to a solution of N-benzyl
ethanol amine (3 g, 0.0198 mol) and triethylamine (3 g, 0.0298 mol)
in 25 ml of DCM (dry) and stirred at RT for 3 h under nitrogen
atmosphere. The reaction was quenched with water, extracted with
dichloromethane, washed with water, brine and dried over sodium
sulfate. Solvent evaporation under reduced pressure followed by
column chromatography over silica gel using 3.5% methanol in
dichloromethane as eluent afforded 4 g of the sub-title compound as
a liquid.
(ii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-y-
l]ethyl}-N',N'-dimethylurea
[0261] Oxalyl chloride (1.14 g, 9 mmol) was added at -78.degree. C.
to a solution of DMSO (1.05 g, 13.5 mmol) in dry dichloromethane
(10 ml) and stirred for 30 min.
1-Benzyl-1-(2-hydroxy-ethyl)-3,3-dimethyl-urea (1.05 g, 13.5 mmol;
from step (i) above) in dry dichloromethane (10 ml). (1 g, 4.5
mmol) was added dropwise at same temperature and stirring continued
for 3 h at the same temperature. Triethylamine (1.8 ml, 12.9 mmol)
was added at -78.degree. C. and the reaction mixture was warmed to
-30.degree. C. Reaction mixture was quenched with 10% aq. citric
acid (10 ml) and extracted with dichloromethane. The organic layer
was washed with brine and dried over sodium sulfate. Solvent
evaporation under reduced pressure yielded 0.79 g of crude aldehyde
as a liquid.
[0262] This (0.75 g, 3.4 mmol) was then taken in DCM (25 ml),
4-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-ylmethyl)benzonitrile (960
mg, 3.4 mmol) was added at 0.degree. C. The reaction mixture was
stirred at RT overnight, quenched with water and extracted with
dichloromethane. Organic layer was washed with water and brine and
dried over sodium sulfate. Solvent evaporation under reduced
pressure followed by purification by column chromatography over
silica gel using 6.5% methanol in dichloromethane as eluent yielded
0.5 g of the desired product. This was further purified by prep
HPLC to give 0.3 g of the title compound as off white solid.
[0263] API-MS: (M+1)=448
Example 14
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]eth-
yl}acetamide
(i) N-Benzyl-N-(2-hydroxy-ethyl)-acetamide
[0264] Acetyl chloride (0.858 g, 10.8 mmol) was added drop by drop
to a solution of N-benzyl ethanol amine (1.5 g, 9.9 mmol) and
triethylamine (1.5 g, 14.9 mmol) in dry dichloromethane (20 ml) at
0.degree. C. under nitrogen atmosphere and stirred at room
temperature overnight. The reaction was quenched with water and
extracted with dichloromethane. The organic layer was washed with
water, 10% aq. NaHCO.sub.3, brine and dried over sodium sulfate.
Solvent evaporation under reduced pressure, followed by column
chromatography over silica gel using 5% methanol in dichloromethane
as eluent afforded 0.68 g of the desired product as an oil.
(ii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-y-
l]ethyl}acetamide
[0265] Oxalyl chloride (0.57 g, 4.5 mmol) was added at -78.degree.
C. to a solution of DMSO (0.63 ml, 9 mmol) in dry dichloromethane
(5 ml) and stirred for 15 min.
N-Benzyl-N-(2-hydroxy-ethyl)-acetamide (0.58 g, 3 mmol; from step
(i) above) dissolved in dry dichloromethane (5 ml) was added
dropwise at the same temperature and stirring continued for 3 h at
the same temperature. Triethylamine (2.1 ml, 15 mmol) was added at
-78.degree. C. and the reaction mixture was warmed to -30.degree.
C. Reaction mixture was quenched with 10% aq. citric acid (10 ml)
and extracted with dichloromethane. The organic layer was washed
with brine and dried over sodium sulfate. Solvent evaporation under
reduced pressure yielded 0.51 g of crude aldehyde. This (0.51 g,
2.6 mmol) was then taken in DCM (10 ml),
4-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-ylmethyl)benzonitrile,
hydrogen chloride salt (0.57 g, 2.6 mmol; from step M (ii) above)
and molecular sieves (500 mg) and stirred for 1 h at room
temperature. NaBH.sub.3CN (0.24 g, 3.9 mmol) was added at 0.degree.
C. and stirring continued overnight under nitrogen atmosphere. The
reaction was quenched with water and extracted with
dichloromethane. The organic layer was washed with water and brine
and dried over sodium sulfate. Solvent evaporation under reduced
pressure followed by purification by column chromatography (two
times) over silica gel using 3% methanol in dichloromethane as
eluent yielded 430 mg desired product. This (430 mg) was again
purified by prep HPLC using 1% acetic acid in acetonitrile as
eluent. Acetonitrile was then evaporated under reduced pressure and
the residue was partitioned between 10% NaHCO.sub.3 and DCM.
Organic layer was then washed with water and brine and dried over
sodium sulfate. Solvent evaporation under reduced pressure afforded
(150 mg) of the title compound as a liquid.
[0266] API-MS: (M+1)=419
Example 15
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]eth-
yl}propane-2-sulfonamide
(i) Benzyl-(2-hydroxy-ethyl)-carbamic acid tert-butyl ester
[0267] (Boc).sub.2O (7.9 g, 0.036 mol) was added drop by drop at
0.degree. C. to a solution of N-benzyl ethanol amine (5 g, 0.033
mol) in dry dichloro methane (50 ml) and stirred at room
temperature overnight under nitrogen atmosphere. The reaction was
quenched with water, extracted with dichloromethane, washed with
brine and dried over sodium sulfate. Solvent evaporation under
reduced pressure followed by purification over silica gel using 10%
ethyl acetate in petroleum ether as eluent afforded the sub-title
compound (3.2 g) as an oil.
(ii)
Benzyl-{2-[7-(4-cyano-benzyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl]-
-ethyl}-carbamic acid tert-butyl ester
[0268] Dry DMSO (1.8 g, 0.0237 mol) was added to a solution of
oxalyl chloride (1.5 g, 0.01185 mol) in dry dichloro methane (25
ml) at -78.degree. C. and stirred for 10 min.
Benzyl-(2-hydroxy-ethyl)-carbamic acid tert-butyl ester (2 g,
0.0079 mol; from (i) above) in 15 ml of DCM was added dropwise at
the same temperature and stirring continued at same temperature for
3 h. Triethylamine (5.5 ml) was added, the reaction mixture was
warmed to -30.degree. C. and quenched with 10% aq. citric acid. The
compound was extracted with dichloromethane, washed with water and
brine and dried over sodium sulfate. Solvent evaporation under
reduced pressure afforded the desired aldehyde (2.5 g) as an
liquid. This (2.5 g, 10 mmol) was then added to a mixture of
4-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-ylmethyl)benzonitrile,
hydrogen chloride salt (1.98 g, 8 mmol, from. M(i) above) and
MgSO.sub.4 (2 g) in dry dichloromethane (10 ml) and stirred for 4 h
under nitrogen atmosphere. Methanol (10 ml), followed by
NaBH.sub.3CN (0.76 g, 12 mmol) was added and the reaction mixture
was stirred overnight. The reaction was quenched with water,
extracted with dichloromethane, washed with brine and dried over
sodium sulfate. Solvent evaporation under reduced pressure followed
by purification over silica gel using 3% methanol in chloroform as
eluent afforded the desired product (1.1 g) as an off white
solid.
(iii)
4-[7-(2-Benzylamino-ethyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-ylmet-
hyl]-benzonitrile
[0269] Dioxane saturated with HCl gas (10 ml) was added to a
solution of
benzyl-{2-[7-(4-cyano-benzyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl]-eth-
yl}-carbamic acid tert-butyl ester (0.65 g, from step (ii) above in
5 ml of dioxane and stirred for 1 h at RT under nitrogen
atmosphere. The reaction mixture was diluted with dry diethylether,
and the solvent was decanted. Precipitated solid was washed with
dry diethylether (4 times) and dried under vacuum to give HCl salt
of the sub-title compound (0.5 g) as a powder.
(iv)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-y-
l]ethyl}propane-2-sulfonamide
[0270]
4-[7-(2-Benzylamino-ethyl)-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-ylme-
thyl]-benzonitrile (0.5 g, 1.33 mmol, from step (iii) above) was
taken in 30 ml of DCM/10% aq. NaHCO.sub.3 (1:1) and stirred for 15
min. Isopropane sulfonyl chloride (0.28 g, 1.99 mmol) was added and
stirring continued at RT for 1.5 h. The organic layer was
separated, washed with brine and dried over sodium sulfate. Solvent
evaporation under reduced pressure followed by purification over
silica gel using 10% ethyl acetate in petroleum ether as eluent
afforded the desired product (280 mg) as white solid. This was
further purified by prep HPLC (0.1% TFA in acetonitrile),
evaporated under reduced pressure, and the residue was partitioned
between sat NaHCO.sub.3 and DCM. The organic layer was washed with
brine and dried over sodium sulfate. Solvent evaporation under
reduced pressure afforded the title compound (140 mg) as an
off-white solid.
[0271] API-MS: (M+1)=483
Example 16
[0272] The following compounds were prepared, from appropriate
intermediates (such as those described hereinbefore), according to
or by analogy with methods described herein: [0273] (i)
tert-butyl[2-(7-{2-[[2-(4-cyanophenoxy)ethyl]
(methylsulfonyl)-amino]ethyl}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl-
]-carbamate; [0274] (ii) tert-butyl {2-[7-(2-{(aminocarbonyl)
[2-(4-cyanophenoxy)ethyl]-amino}ethyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-
-yl]ethyl}-carbamate; [0275] (iii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-methoxyphenyl)-2-oxoethyl]-9-ox-
a-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0276]
(iv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-methoxyphenyl)-2-oxoethyl]-9-ox-
a-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0277] (v)
2-[7-(2-{(aminocarbonyl)
[2-(4-cyanophenoxy)ethyl]amino}ethyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3--
yl]-N-(tert-butyl)acetamide; [0278] (vi)
2-[7-(2-{(aminocarbonyl)[2-(4-cyanophenoxy)ethyl]amino}ethyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl]-N-benzylacetamide; [0279] (vii)
2-[7-(2-{(aminocarbonyl)
[2-(4-cyanophenoxy)ethyl]amino}ethyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3--
yl]-N-(1-methyl-1-phenylethyl)acetamide; [0280] (viii)
N-(tert-butyl)-2-(7-{2-[[2-(4-cyanophenoxy)ethyl]
(methylsulfonyl)amino]ethyl}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)acetam-
ide; [0281] (ix)
N-benzyl-2-(7-{2-[[2-(4-cyanophenoxy)ethyl](methylsulfonyl)-amino]ethyl}--
9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)acetamide; [0282] (x)
2-(7-{2-[[2-(4-cyanophenoxy)ethyl](methylsulfonyl)amino]ethyl}-9-oxa-3,7--
diazabicyclo[3.3.1]non-3-yl)-N-(1-methyl-1-phenylethyl)acetamide;
[0283] (xi)
tert-butyl[2-(7-{2-[[3-(4-cyanophenyl)propyl](methylsulfonyl)-amino]-
ethyl}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-carbamate;
[0284] (xii)
N-(tert-butyl)-2-(7-{2-[[3-(4-cyanophenyl)propyl](methylsulfonyl)-a-
mino]ethyl}-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)acetamide; [0285]
(xiii)
N-[2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[3-(4-cyano-
phenyl)propyl]methanesulfonamide; [0286] (xiv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(2,6-dimethylphenoxy)ethyl]-9-oxa--
3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0287] (xv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-di-
azabicyclo[3.3.1]non-3-yl}ethyl)urea; [0288] (xvi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-methoxyphenyl)ethyl]-9-oxa-3,7--
diazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0289] (xvii)
N-(2-{7-[2-(4-acetylphenyl)ethyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}-
ethyl)-N-[2-(4-cyanophenoxy)ethyl]urea; [0290] (xviii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2-phenylethyl)-9-oxa-3,7-diazabicycl-
o[3.3.1]non-3-yl]ethyl}urea; [0291] (xix)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(3-fluorophenyl)ethyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)urea; [0292] (xx)
N-(2-{7-[(2-chloropyridin-3-yl)methyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non--
3-yl}ethyl)-N-[2-(4-cyanophenoxy)ethyl]methanesulfonamide; [0293]
(xxi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(6-methoxypyridin-3-yl)methyl]-9-oxa-
-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0294]
(xxii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(4,5-dimethyl-2-furyl)methyl]-9-oxa--
3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0295]
(xxiii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(trifluoromethyl)benzyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0296]
(xxiv)
N-{2-[7-(4-chlorobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[-
2-(4-cyanophenoxy)ethyl]methanesulfonamide; [0297] (xxv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(difluoromethoxy)benzyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0298]
(xxvi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(methylsulfonyl)benzyl]-9-oxa-3,7--
diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0299]
(xxvii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2-fluorobenzyl)-9-oxa-3,7-diazabicyc-
lo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0300] (xxviii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2,4-difluorobenzyl)-9-oxa-3,7-diazab-
icyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0301] (xxix)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2,5-dichlorobenzyl)-9-oxa-3,7-diazab-
icyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0302] (xxx)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[3-(trifluoromethyl)benzyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0303]
(xxxi)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[2-
-(4-cyanophenoxy)ethyl]methanesulfonamide; [0304] (xxxii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(2,6-dichloropyridin-4-yl)methyl]-9--
oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0305] (xxxiii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(pyridin-4-ylmethyl)-9-oxa-3-
,7-diazabicyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0306]
(xxxiv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(3,5-dimethylisoxazol-4-yl)methyl]-9-
-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0307] (xxxv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(2,4-dimethyl-1,3-thiazol-5-y-
l)methyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0308] (xxxvi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[(1-methyl-1H-imidazol-2-yl)methyl]-9-
-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide;
[0309] (xxxvii)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(3-phenylpropyl)-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0310]
(xxxviii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[3-(4-cyanophenyl)propyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0311] (xxxix)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[3-(3-methoxyphenyl)propyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0312] (xl)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2,6-dimethylbenzyl)-9-oxa-3,7-diazab-
icyclo[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0313] (xli)
N-{2-[7-(4-tert-butylbenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-
-N-[2-(4-cyanophenoxy)ethyl]methanesulfonamide; [0314] (xlii)
N-[2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]-N-[2-(4-cyano-
phenoxy)ethyl]-N',N'-dimethylurea; [0315] (xliii)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[2-
-(4-cyanophenoxy)ethyl]-N',N'-dimethylurea; [0316] (xliv)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-fluoro-4-(trifluoromethyl)benzyl]--
9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea;
[0317] (xlv)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(4-fluorobenzyl)-9-oxa-3,7-diaz-
abicyclo[3.3.1]non-3-yl]ethyl}-N',N'-dimethylurea; [0318] (xlvi)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[4-(difluoromethoxy)benzyl]-9-oxa-3,7-
-diazabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea; [0319]
(xlvii)
N-[2-(4-cyanophenoxy)ethyl]-N',N'-dimethyl-N-{2-[7-(2-phenylethyl)-9-oxa--
3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}urea; [0320] (xlviii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-di-
azabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea; [0321] (xlix)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(3-fluorophenyl)ethyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)-N',N'-dimethylurea; [0322] (l)
N-[2-(4-cyanophenoxy)ethyl]-N',N'-dimethyl-N-{2-[7-(3-phenylpropyl)-9-oxa-
-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}urea; [0323] (li)
N-[2-(4-cyanophenoxy)ethyl]-N-{2-[7-(2-phenylethyl)-9-oxa-3,7-diazabicycl-
o[3.3.1]non-3-yl]ethyl}methanesulfonamide; [0324] (lii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-di-
azabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0325] (liii)
N-[2-(4-cyanophenoxy)ethyl]-N-(2-{7-[2-(4-fluorophenyl)ethyl]-9-oxa-3,7-d-
iazabicyclo[3.3.1]non-3-yl}ethyl)methanesulfonamide; [0326] (liv)
N-benzyl-N-(2-{7-[2-(4-cyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]n-
on-3-yl}ethyl)methanesulfonamide; [0327] (lv)
N-(2-{7-[2-(4-cyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}-
ethyl)-N-(2-phenylethyl)methanesulfonamide; [0328] (lvi)
N-(2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl-
}ethyl)-N-(2-phenylethyl)methanesulfonamide; [0329] (lvii)
N-(2-{7-[2-(4-cyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}-
ethyl)-N-(2-phenoxyethyl)methanesulfonamide; [0330] (lviii)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(2-
-phenoxyethyl)methanesulfonamide; [0331] (lix)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(2-
-phenylethyl)methanesulfonamide; [0332] (lx)
N-(2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl-
}ethyl)-N-(2-phenoxyethyl)methanesulfonamide; [0333] (lxi)
N-benzyl-N-{2-[7-(4-fluorobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]-
ethyl}methanesulfonamide; [0334] (lxii)
N-benzyl-N-{2-[7-(4-chlorobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]-
ethyl}methanesulfonamide; [0335] (lxiii)
N-(2-cyanobenzyl)-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]no-
n-3-yl]ethyl}methanesulfonamide; [0336] (lxiv)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(4-
-fluorobenzyl)methanesulfonamide; [0337] (lxv)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(3-
-fluorobenzyl)methanesulfonamide; [0338] (lxvi)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-[4-
-(difluoromethoxy)benzyl]methanesulfonamide; [0339] (lxvii)
N-(4-chlorobenzyl)-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]n-
on-3-yl]ethyl}methanesulfonamide; [0340] (lxviii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}ethanesulfonamide; [0341] (lxix)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}-N'-methylurea; [0342] (lxx)
N-benzyl-N-(2-{7-[2-(4-cyanophenyl)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]no-
n-3-yl}ethyl)methanesulfonamide; [0343] (lxxi)
N-benzyl-N-(2-{7-[2-(2,4-dicyanophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3-
.1]non-3-yl}ethyl)methanesulfonamide; [0344] (lxxii)
N-benzyl-N-(2-{7-[3-(4-cyanophenoxy)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]-
non-3-yl}ethyl)methanesulfonamide; [0345] (lxxiii)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]et-
hyl}-1,1,1-trifluoromethanesulfonamide; [0346] (lxxiv)
N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]e-
thyl}urea; and [0347] (lxxv)
N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}-N-(4-
-fluorobenzyl)urea;
[0348] or a pharmaceutically acceptable derivative thereof.
Example 17
[0349] Title compounds of the above Examples were tested in Test A
above and were found to exhibit D.sub.10 values of more than
5.5.
Example 18
[0350] Title compounds of the above Examples were tested in Test B
above and were found to exhibit pIC.sub.50 values of greater than
4.5. Indeed the compounds of Examples 2, 3 and 9(xlvi) were found
to have pIC.sub.50 values of 5.55, 5.8 and 5.38, respectively.
Abbreviations
[0351] Ac=acetyl [0352] API=atmospheric pressure ionisation (in
relation to MS) [0353] aq.=aqueous [0354] br=broad (in relation to
NMR) [0355] Bt=benzotriazole [0356] t-BuOH=tert-butanol [0357]
CI=chemical ionisation (in relation to MS) [0358]
MCPBA=meta-chloroperoxybenzoic acid [0359] d=doublet (in relation
to NMR) [0360] DBU=diazabicyclo[5.4.0]undec-7-ene [0361]
DCM=dichloromethane [0362] dd=doublet of doublets (in relation to
NMR) [0363] DMAP=4-dimethylaminopyridine [0364]
DMF=N,N-dimethylformamide [0365] DMSO=dimethylsulfoxide [0366]
EDC=1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide [0367] Et=ethyl
[0368] EtOAc=ethyl acetate [0369] eq. equivalents [0370]
ES=electrospray (in relation to MS) [0371] FAB=fast atom
bombardment (in relation to MS) [0372] FBS=foetal bovine serum
[0373] h=hour(s) [0374] HCl=hydrochloric acid [0375]
HEPES=4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [0376]
HPLC=high performance liquid chromatography [0377] IMS=industrial
methylated spirits [0378] IPA=iso-propyl alcohol (propan-2-ol)
[0379] m=multiplet (in relation to NMR) [0380] Me=methyl [0381]
MeCN=acetonitrile [0382] MeOH=methanol [0383] min.=minute(s) [0384]
m.p.=melting point [0385] MS=mass spectroscopy [0386]
NADPH=nicotinamide adenine dinucleotide phosphate, reduced form
[0387] OAc=acetate [0388] Pd/C=palladium on carbon [0389] q=quartet
(in relation to NMR) [0390] rt=room temperature [0391] S=singlet
(in relation to NMR) [0392] t=triplet (in relation to NMR) [0393]
TEA=triethylamine [0394] TIPE=tetrahydrofuran [0395] tlc=thin layer
chromatography Prefixes n-, s-, i-, t- and tert- have their usual
meanings: normal, secondary, iso, and tertiary.
* * * * *